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1.   Introduction 
1.1. Conventional treatment for lung cancer 
 
Because of the most important avoidable cancer risk of huge tobacco consumption, 
approximately 100 million mortalities were associated with tobacco-caused diseases, 
including lung cancer, cardiovascular disease and stroke in the 20
th
 century (Gandini et 
al., 2008).  
Lung cancer is the disease of uncontrolled cell growth in the lung and 90% of cases are 
related to smoking (Hecht et al., 2009). Lung cancer remains the leading cause of 
cancer-related death in industrial countries and accounted for 30% of all male cancer 
deaths and 26% of all female cancer deaths in 2010 (Jemal et al., 2011). It is reported 
that approximately 80% of lung cancer cases are non-small cell lung cancer (NSCLC), 
including adenocarcinoma, squamous cell carcinoma or large cell carcinoma, and 40% 
of patients with NSCLC are with locally advanced and/or unresectable diseases (Rosell 
et al., 2006).  
Nowadays, the standard approaches for the treatment of NSCLC are surgery, 
chemotherapy and radiation therapy. They can be used either alone or in combination 
depending on tumor size, location and histology (Jassem, 2007, Coory et al., 2008). 
Surgical resection is the major potentially curative therapeutic option for NSCLC in 
early stage (stage I and II), whereas inoperable early stage NSCLC is often treated by 
radiotherapy (Erman et al., 2004; Bogart et al., 2005, Scott et al., 2007). Chemotherapy 
combined with radiation therapy is commonly applied for NSCLC in advanced stages 
(stage III and IV). In last couple of decades, many approaches to multimodality therapy 
have been studied in patients with NSCLC. Modern technical development in radiation 
therapy including intensity modulated radiation therapy, image guided radiation therapy 
and more accurate dose calculation algorithms has been shown to improve local control 
of resected advanced NSCLC (Haasbeek et al., 2009). Unfortunately, the latter has 
failed to translate in an improvement in patient survival due to the frequent recurrence 
and metastases appearing even after aggressive treatment schedules (Rengan et al., 
2011). 
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1.2. Charged particle beam radiation therapy 
1.2.1. Charged particle radiation 
 
One of the most important points during radiation therapy of cancers is to concentrate a 
precisely prescribed dose to the target volume while minimizing the dose to surrounding 
normal critical structures. The superior biophysical and biological profiles of particle 
beams such as carbon beam and protons with excellent dose localization and sparing of 
normal tissues make them highly attractive for treating malignant tumors including lung 
cancer (Kraft et al., 1998; Lomax et al., 2001, Chen et al., 2004, Fokas et al., 2009; 
Minohara et al., 2010) 
Particle radiation is the radiation of energy by emitting of fast-moving subatomic 
particles, such as protons or ions, in the form of positively or negatively charged 
particles. Photons, neutrons and neutrinos are uncharged particles, while electrons, 
protons, alpha particles and heavier atomic ions are charged particles (Schulz-Ertner et 
al., 2007). The charged particle radiation therapy uses a wide range of different beams 
of protons or other charged particles, such as helium, carbon, neon, or silicon (Terasawa 
et al., 2009). In 1946, R. Wilson mentioned the advantage of Bragg Peak (Fig. 1) and 
proposed the clinical application of high energy protons and heavier ions in treating the 
deep sheeted tumor (Wilson, 1946). In 1948, R. Stone and JC. Larkin used fast neutrons 
to treat patients with advanced incurable cancer in various sites (Stone, 1948). But the 
neutron trial was terminated because of severe side effects in spite of good tumor 
control rates. Pioneering clinical studies of particle radiotherapy were performed in 
1950’s to treat patients with proton and later on with helium ion at Lawrence Berkeley 
Laboratory in California (Tobias et al. 1952). Because of the prospective superiority of 
depositing the maximum energy at the range end with less scattering than when using 
conventional X-ray, carbon ion beams become one of the first candidates of substitutes 
for currently clinical use. The expanding interest in particle therapy has intensified the 
effort to better understand the particle irradiation both at the physical and the biological 
sides (Schulz-Ertner et al., 2007). 
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1.2.2. Biological advantages of charged particle radiation 
 
 
Fig. 1. Schematic diagram of Bragg Peak. The dose produced by a carbon ion 
beam and by a proton beam in passing through water, compared to the absorption 
of a photon beam (Fokas et al., 2009). 
      
Fig. 2. Relationship of linear energy transfer (LET, 100 KeV/μm) and Relative 
Biologic Effectiveness (RBE) for carbon ions (Franken et al., 2011).  
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The conventional radiotherapy has been utilizing X-ray beams, which deposit the 
maximum dose within a few centimeters of the skin surface proximal to the intended 
target and continue to irradiate beyond the region targeted for treatment. Obviously, this 
energy distribution trajectory of X-ray beams has certain advantages in curing skin 
cancers, such as basal cell carcinoma, and malignant melanoma. However, tumors 
centrally located in the body could only receive 60 to 70% of the total dose 
administered with each individual X-ray beam, while the surrounding tissues were 
unavoidably affected (Fokas et al., 2009). 
Thanks to its superior physical properties, irradiation therapy using high-energy charged 
beams, such as carbon ions, have several advantages when compared with the 
conventional irradiation with photons.  
 
1). Charged particle beam has higher relative biological effectiveness (RBE) 
A major concept in estimating the efficacy of charged particle beams is RBE. The RBE 
is defined as the ratio of the absorbed doses of two different radiation beams required 
that results in the same biological effect. The RBEs between different radiation beams 
are varied, depending on many parameters, including the biological endpoint, 
fractionated dose, particle type and energy, as well as the oxygenation status of tissue 
irradiated (Weyrather et al., 2004). Therefore, the RBE is patient specific in every 
location in the treatment fields and has to be precisely calculated by sophisticated 
scientists prior to clinical practice.  
Another concept to define the ionizing density alone a particle track is linear energy 
transfer (LET). The conventional photon beams deposit most of their energy near the 
surface (skin and normal tissues in clinical therapy) and decrease in the dose profile 
with depth when going through matters (e.g. normal tissues beyond the tumor). In 
contrast, charged particle beam exhibits a LET, which penetrates with increasing depth 
and reaches a maximum in the Bragg peak region (Kraft, 1998).  
Carbon ions and neutrons are high-LET beams, when compared to the low-LET proton 
and photon beams, thus, under the same circumstances, heavier ion beam with 
higher-LET shows higher RBE (Bassler et al., 2010). 
 
2). Charged particle beam causes more severe damage to cells 
Since the very beginning of the 19
th
 century, abundant studies had reported the harmful 
effects of radiation. Low-LET radiations can cause cellular damages to nucleotide bases, 
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cross-linking, DNA single- and double-strand breaks (DSBs), and genomic instabilities. 
Base excision repair and nucleotide excision repair are the common ways for individual 
cells to recover its functions (Goodhead et al., 1993; Eckardt-Schupp et al., 1999). 
Charged particle beams cause more severer DNA damages, known as clustered damage, 
which is difficult, even impossible, to repair (Goodhead, 1994). Previous studies 
showed that after high-LET beam irradiations, at least 70% of DSBs caused contain 
more than two breaks and show higher complexity than with low-LET beams (Kraft et 
al., 1992; Goodhead, 1999). When DNA damage heavily clustered, the repair of base 
damage become relative slow and can create further DSBs, which can lead to possible 
linkage on different chromosomes and derive molecular inventories (Dianov et al., 2001; 
Singleton et al., 2002). 
 
3) Charged particle beam exhibits lower oxygen enhancement ratio (OER) 
As a tumor grows, the oxygen concentration in the tumor region is usually lower than in 
the normal tissue area, which is due to the great oxygen demand to support the rapid 
tumor growth. Tumor hypoxia is a well-recognized factor contributing to tumor 
progress, angiogenesis and genetic instability and is one of the limiting factors in cancer 
radiotherapy (Bassler et al., 2010). The OER is the ratio of radiation dose in the absence 
of oxygen to the dose in the presence of oxygen required for the same biological effect. 
Previous studies of OER found that the OER for conventional radiation therapy with 
photons is much higher (about 3) than the OER for heavy ions (only 1.5 to 1.8) 
(Skarsgard, 1998; Furusawa et al., 2000). The potential of carbon ion radiotherapy in 
overcoming hypoxia-induced resistance has been demonstrated in clinical study of 
cervical cancer (Nakano et al., 2006). This trial involved cervical cancer patients treated 
with a 400 MeV per nucleon carbon ion beam. The similar disease-free survival and 
local control between hypoxic and oxygenated tumors indicated that the role of the 
tumor oxygenation status was not important in carbon ion therapy. 
 
The superior biophysical and biological profiles of carbon beam radiation with 
high-LET of excellent dose localization, high biological effect and sparing of normal 
tissues, make it highly attractive for treating malignant tumors including lung cancer. 
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1.2.3. Charged particle radiation applied in cancer therapy 
 
The pioneering clinical studies of charged particle therapy can go back to 1950s, which 
were performed at accelerators built for physics research (Tobias et al. 1952). But the 
first hospital-based proton facility was commissioned in 1990 at the Loma Linda 
University Medical Center in USA and the first hospital-based heavy ion facility was 
constructed in 1993 at National Institute of Radiological Sciences in Japan (Gademann 
et al., 1990, Hirao 1992, Schulz-Ertner et al., 2007). Parallel to the continuously 
development in the field of the facilities, that provide X-rays, electrons, light and also 
heavy ions, the interest of charged particle therapy of cancer have been increasing 
substantially all over the world within the last two decades. Nowadays, ion irradiation 
using protons and heavier ions such as carbon beams are widely applied both 
experimentally and clinically (Pijls-Johannesma et al., 2008). Until end 2010, 
approximately 84,900 patients have been treated worldwide with particle radiotherapy. 
Of them, about 6,660 patients have received carbon ion therapy in Japan and Germany 
(PTCOG, 2010).  
Carbon ion radiotherapy showed a specific effectiveness in local control of different 
types of cancer. Between 1994 and 2005, 2,371 patients with malignant tumors were 
registered in phase I/II dose-escalation studies and clinical phase II trials using 
hypofractionated carbon ion therapy. Compared with conventional radiotherapy, carbon 
ion beams can reduce the overall treatment times and also achieve better local tumor 
control, even for radio-resistant tumors such as malignant melanoma, hepatocellular 
carcinoma and bone/soft tissue sarcomas with minimal morbidity to the normal 
surrounding tissues (Ishikawa et al., 2006; Okada et al., 2010).  
 
1.2.4. Charged particle radiation applied in NSCLC  
 
Carbon ion therapy has also been investigated in the patients suffering from NSCLC. In 
a prospective nonrandomized phase I to II trial in Japan, different dose fractionation 
scheme for carbon ion has been tested in 81 patients with stage I NSCLC, who were not 
candidates for surgical resection. The optimum safety and efficacy dose were 
investigated by conducting different radiation fractions and dose escalation methods to 
two groups of patients. The optimal dose of carbon ions was determined to be 68.4 to 
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79.2 GyE (photon gray equivalents) administered in 9 fractions. The five-year local 
control and overall survival rate were 84%, and 45%, respectively (Kadono et al., 2002, 
Miyamoto et al., 2003). Proton radiation therapy using 50-76 GyE in 10 or 20 fractions 
in clinical trials has received five-year local control rates of 89% and 39% for stage IA 
and stage IB NSCLC, respectively. The overall survival rates for these two groups were 
70% and 16%, respectively (Shioyama et al., 2003, Nihei et al., 2006). A recently 
reported meta-analysis compared the treatment effectiveness of photon, proton and 
carbon radiation therapy. The results demonstrated that five-year overall survival for 
conventional radiotherapy (20%) was statistically significantly lower than that for 
stereotactic radiotherapy (42%), proton therapy (40%) and carbon-ion therapy (42%) 
(Grutters et al., 2010). 
Several research groups have performed evaluations of the tumor response and the side 
effects of patients NSCLC after carbon ion therapy. Miyamoto et al. (2003) reported in 
3.7% of the patients had acute side effects (grade 3 and more) and 1.2% had late side 
effects (grade 3 and more). In the recently published phase I/II trial of the same 
investigators were a total dose of 52.8–60 GyE was delivered over 1 week, no grade 3+ 
acute or late toxicity was observed. These clinical data indicated that carbon ions 
therapy can especially reduce late side effects and is safe and feasible in the treatment of 
NSCLC (Miyamoto et al., 2003, Pijls-Johannesma et al., 2008). However, randomized 
trials to compare different techniques of radiation therapy are needed to clarify the 
application of carbon ions radiation therapy in NSCLC in advanced stage. 
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1.3. Gene expression changes induced by irradiation 
 
Fig.3. Radiation induced a serials of biological responses progressed in different 
levels (Feinendegen et al., 2008) 
 
DNA DSB is thought to be the lethal lesion caused by ionizing radiation and can result 
in rearrangement of genetic information, leading to cell death or carcinogenesis. DNA 
damage includes activation of a number of signal transduction cascades and stimulates 
several components in concert to activate the cellular checkpoint, which leads to cell 
cycle delay, DNA repair and programmed cell death (Jeggo et al., 2006). The alterations 
in gene expression also represent a central component of the pathways involved. Studies 
of altered gene expression have historically played an important role in elucidating the 
molecular mechanisms underlying cellular radiation response (Eckardt-Schupp et al., 
1999; Feinendegen et al., 2008). 
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1.3.1. Gene expression changes induced by X-ray 
 
Several studies of X-ray interactions in DNA have provided evidence for DNA damage 
which also has a high probability of producing DSBs. These cellular changes may 
initiate neoplastic transformation of the cell and diverse effects on differentiation and 
growth (Nakano et al., 1994). The primary studies of the progressive nature of 
carcinogenesis were predicted in vivo. Since 1978, in vitro transformation system has 
been used to study the molecular mechanism of multistep carcinogenesis (Barrett et al., 
1978). 
After exposure to radiations, cell cycle delay is often found in mammalian cells. It is 
generally hypothesized that this delay provides damaged cells additional time to 
self-repair before the cell enters critical periods of the cell cycle (Murnane, 1995). It is 
widely known that CDKN1A (p21) protein is an inhibitor of cyclin-dependent kinases 
(CDK), a family of protein kinases known as key regulators of cell cycle progression. 
Never the less, CDKN1A can inhibit several CDK and most effective toward G1/S 
cyclins. Other CDK inhibitors, such as CDKN1B (p27) and CDKN2B (p15) are 
activated by irradiation and contribute to the G1 arrest. Moreover, radiation-induced G2 
arrest was shown to require inhibitory phosphorylation of the kinase CDC2 via an ATM 
(ataxia telaniectasia mutated)-dependent pathway (Abbas and Dutta, 2009). The 
expression of CDKN1A protein after exposure to irradiations is generally accepted as an 
indicator of cells with a wild-type p53 (Nakano et al., 1994). Radiation induced DNA 
DSB often lead to the activation of p53 through ATM pathway and to induce apoptosis 
(Banin et al., 1998). 
Henness et al. reported that fractionated X-ray treatment alone can produce increased 
radiation and drug resistance in SCLC cells, which was due to the decreased expression 
of BCL2 and glutathione-S-transferase-π and increased expression of multidrug 
resistance-associated protein 1 (MRP1), MRP2, N-myc and topoisomerase-IIα (Henness 
et al., 2002). The CGRP (calcitonin gene-related peptide) and substance P, the two 
major neuropeptides released by sensory neurons, are overexpressed after irradiation 
and have opposing effects during development of intestinal radiation injury (Wang et al., 
2006). Down-regulation in response to low dose X-ray (0.1-0.3 Gy) was observed in 
mRNA level of CDC2, cyclin A, cyclin B, thymidine kinase, topisomeras IIa, and 
RAD51 (de Toledo et al., 1998).  
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1.3.2. Gene expression changes induced by heavy ion beams  
 
Although heavy ion have been applied in clinical therapy of cancers for many years, the 
genetic mechanisms and the signaling pathways involved in cellular responses to heavy 
ion radiation are not completely understood. Several previous studies have evaluated the 
correlation between cellular responses to carbon ion irradiation and the expression 
status of known genes involved in the regulation of cell cycle, DNA repair, and 
apoptosis using analytical approach for single gene. Recent studies demonstrated that 
irradiation with carbon beams induced not only apoptosis, but also cellular senescence 
in glioma cells with either wild-type or mutant p53 expression, more effectively than 
X-ray (Guida et al., 2005; Jinno-Oue et al., 2010). Using semiquantitative real time 
PCR, significant different expressions of 10 selected genes involved in DNA repair have 
been showed to be responsible to inhibition of potential lethal damage repair in cultured 
lung cancer cells after carbon ion irradiation compared to X-ray (Yashiro et al., 2007). 
The expression and focus formation of CDKN1A, a member in the complex of 
MRE11/RAD50/NBS1 ensuring DSB repair, is correlated with the traversal of ionizing 
particles (Jakob et al., 2002). Through pathological investigation and 
immunohistochemical analysis of CDKN1A, carbon ion has been found to be 
responsible for cell cycle arrest in tumor cells with mitotic catastrophe (Imadome et al., 
2008). Recent study using a cDNA expression array containing 161 key genes in 
damage and repair signaling pathway has revealed that 38 and 24 genes were 
differentially altered in breast epithelial cell treated with X-ray and heavy ion (Fe
+2
), 
respectively (Roy et al., 2008).  
Microarray technology are currently used to investigate gene expression profile in 
cancer cells and tumor samples exposed to heavy ions irradiation, but only few exist to 
date. Using single-color oligo-microarrys, Nojiri et al. (2009) compared the gene 
expression profiles of two murine squamous cell carcinomas, which are respectively 
highly radioresistant and radiosensitive. After irradiation with X-ray or carbon ions, 4 
genes, EFNA1, SPRR1A, SRGAP3 and XRRA1 were identified associated with the 
character of radioresistant. In a microarray study of oral squamous cell carcinoma 
(OSCC) cells, 84 genes were greatly modulated after exposure to carbon ions. Of these 
regulated genes, three genes (TGFBR2, SMURF2, and BMP7) and two genes (CCND1 
and E2F3), respectively, were found to be involved in the transforming growth factor 
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beta-signaling pathway and cell cycle:G1/S checkpoint regulation pathway. (Fushimi et 
al., 2008). In a similar study on oral squamous cell carcinoma cells, a set of 98 genes 
was modified after carbon ions irradiation and remained unchanged in their expressions 
after X-ray irradiation. However, clustering analysis of expression profiles among 
metastatic tumors in murine model has showed little difference in nonirradiated, carbon 
ion irradiated, and γ-ray irradiated groups, while same pathologic findings have gained 
among these groups (Tamaki et al., 2009). 
 
1.4. Modern technologies applied in studying of gene functions 
 
Many years of intensive research have demonstrated that the signaling molecules of 
encoded genes with various functions are organized into complex biochemical networks. 
These signaling circuits are complicated systems consisting of multiple elements 
interacting in a multifarious fashion. Actually, the analysis and determination of 
unknown genes interactions as well as their association with diseases often contain 
screening of hundreds of thousands of transcripts and meaningful predictions of sound 
computational algorithms (Li et al., 2009). Therefore, more efficient solutions are in 
urgent need for genetic research. 
The development of automated methods for the study of gene functions is becoming an 
increasingly important area of investigation in bioinformatics and computational 
biology. High-throughput methods such as microarray, allow researchers to perform 
millions of biochemical, genetic or pharmacological tests rapidly and simultaneously. 
The characteristics of cost-effective and high throughput technology are the 
combination of analytical robotics, data processing and control software, liquid 
handling devices and sensitive detectors (Hertzberg et al., 2000). 
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1.4.1. Microarray technology in biomedical and clinical research 
 
 
Fig. 4. Schematic representation of microarray assay of gene expression  
 
As shown in Fig. 4, microscopic arrays of large sets of cDNA sequences or 
oligonucleotides immobilized on solid substrates are multiplex lab-on-a-chip, which can 
analyse hundreds of thousands of biological materials simultaneously via 
high-throughput screening methods (Bhattacharya et al., 2009). Nowadays, microarray 
technology has been applied for comparing genome features among individuals and 
their tissues and cells, and has become one of the standard tools of high-throughput 
analysis in all the aspect of biomedical research (Trevino et al., 2007).  
With this technology it is possible to analyse gene expression patterns for studying the 
genetic changes of tumor progression, the cellular response to chemo- and radiation 
therapy, and drug target identification. According to the published data, many tumor 
subtypes can be identified in reference to the variations (increased or decreased) of gene 
expression or changes in transcriptional profiles (Alizadeh et al., 2000, Kikuchi et al., 
2003, Nagata et al., 2003, Ramaswamy et al., 2003, van’t Veer et al., 2008). Moreover, 
recent studies showed that the utilizes of microarrays are fully widen to detecting single 
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nucleotide polymorphisms, aberrations in methylation patters, alterations in gene 
copy-numbers, alternative RNA splicing and also pathogen detection, but not only 
limited to gene expression. 
 
1.4.2. Microarray technology applied in lung cancer research  
 
The high-throughput microarray analysis of gene expression has been systematically 
used to examine differentially expressed genes, and molecular pathways and to identify 
tumor markers of lung cancer. 
 
Fig. 5. Overview of the utility of gene expression microarray technology in lung 
cancer for discovery of tumor marker and therapeutic target  
 
Using oligonucleotide microarrays consisting 12,600 transcript sequences, 
Bhattacharjee et al. (2001) generated a molecular taxonomy of 186 lung carcinomas 
including 139 adenocarcinomas and defined distinct subclasses of lung adenocarcinoma 
by hierarchical and probabilistic clustering of gene expression. To identify low- and 
high-risk individuals, Beer et al. (2002) analysed a data set of 4,966 genes in 86 lung 
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adenocarcinomas and built a risk index of the top 50 genes by using two equivalent but 
independent training and testing sets. Microarray analysis has been used to predict 
clinical outcome of patients with lung cancer and to determine patients for aggressive 
therapies. By studying a cohort of 86 patients with lung adenocarcinoma, Guo et al. 
(2006) created a 37 gene signature using several bioinformatics tools. The gene 
signature was used to predict the survival of these patients by Kaplan-Meier analysis. 
These patients could be classified into three groups with good, moderate and poor 
prognoses based on the gene expression profiles. Moreover, several groups have 
evaluated gene expression profiles of lung cancer to predict the response to 
chemotherapy and radiation therapy. The gene signature profile identified by Potti et al. 
(2006) predicted recurrence for 89 patients with early stage NSCLC after adjuvant 
therapy significantly better than conventional prognostic factors. These microarray 
studies provided potential clinical applications of gene expression profile in field of 
differentiating diagnosis, prediction of treatment outcome of patients and discovery of 
novel tumor markers for molecular therapy of lung cancer. 
 
1.4.3. Gene expression profiling using microarray technology in cancer 
research  
 
Grouping genes based on functional similarities can systematically enhance biological 
interpretation of large lists of genes derived from high throughput studies, such as 
cDNA microarray analysis (Streit et al., 2009). The most frequent employment of 
microarray in cancer research was to compare gene expression profiling between cells 
with different sensitivity to treatments, including radiation or drugs (Hellman et al., 
2005, Poulsen et al., 2005). In clinical researches, microarray has also been applied to 
test the tumor proliferations in more than 1,000 patients with various tumors (Starmans 
et al., 2008). 
Once upon a time, categorizing of tumors was only based on histological classification 
of cancer samples. Using various microarray chips, the signature of a tumor from an 
individual patient can be diagnosed conveniently (Liotta et al., 2000). As of today, more 
than a dozen studies evaluating lung cancer using DNA microarray technologies as well 
as a meta-analysis have been published (Lu et al., 2006, Liang et al., 2008).  
Although there are many platforms for profiling cancers, including mass spectrometry, 
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antibody arrays (Ostroff et al., 2010) and methylome profiling (Heller et al., 2010), the 
most common methods are microarray chips analysis and qRT-PCR validation 
afterwards (Singhal et al., 2008). 
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1.5. The aim of this study 
 
This study is a cooperation of the GSI (Gesellschaft für Schwerionenforschung) 
Darmstadt and the Philipps-University Marburg. The main goal of this study is to 
increase understanding of the response of NSCLC to heavy ion irradiation. In order to 
achieve this objective, human lung adenocarcinoma cell line A549 was used for 
analysis of the gene expression profiles induced by X-ray and carbon ion irradiation in 
this study.  
 
The study includes specific goals,  
1). Determine the clonogenic survival ability of A549 cells after exposure to X-ray and 
carbon ion irradiation using colony forming assay, 
2). Compare the RBE of X-ray and carbon ion irradiation in A549 cells, 
3). Optimize the experimental conditions for microarray analysis of A549 cells, 
4). Determine and compare the gene expression changes induced by X-ray and carbon 
ion irradiation, 
5). Classify the differently changed genes according to the biological functions and 
analysis the signaling network among them, 
6). Optimize the quantitative methods of gene expression changes in A549 cells, 
7). Validate these differently changed genes 
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2. Materials 
2.1. Cell line 
 
The human lung adenocarcinoma cell line A549 was purchased from the American Type 
Culture Collection (ATCC, Manassas,
 
VA). The cells were derived through explant 
culture of lung carcinomatous tissue from a 58-year-old Caucasian male (Giard et al., 
1973).  
 
2.2. Primers 
 
Table.1. Primer sequences and PCR conditions. 
Gene   
Entrez 
Gene ID 
 
Forward primer (5'-3') 
Reverse primer(5'-3') 
 
Product 
Size (bp) 
CCND2  894  
TACCACTATGGGGTCAGC 
GTGGCCACCATTCTGCGC 
 181 
CDCA5  113130  
CATCTCCTACTAAGCCTCTGCG 
CGATCCTCTTTAAGACGATGGG 
 132 
CDC14B  8555  
GTGCCATTGCAGTACATT 
AGCAGGCTATCAGAGTG 
 123 
CDC25B  994  
CCGCTCAAAATCACTGTGTCA 
GCTCTTCAGTAGGAAGCTCTCG 
 298 
CDKN1A  1026  
CCTGTCACTGTCTTGTACCCT 
GCGTTTGGAGTGGTAGAAATCT 
 130 
E2F5  1875  
TCAGGCACCTTCTGGTACAC 
GGGCTTAGATGAACTCGACTC 
 145 
RARG  5916  
TACCACTATGGGGTCAGC 
CCGGTCATTTCGCACAGCT 
 195 
TP53I11  9537  
ATCAGCCAGGTCTTAGGCAAT 
GCCGTGTAGAGCGTTCC 
 242 
       
GAPDH  2597  
TGGTCACCAGGGCTGCTT 
AGCTTCCCGTTCTCAGCCTT 
 150 
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2.3. Chemicals 
 
ABsolute SYBR Green Mixes ABgene, Germany 
Agarose Sigma Aldrich, Germany 
Ampicillin PAA, Germany 
DEPC Sigma Aldrich, Germany 
Distilled water Millipore, Germany 
DMSO Sigma Aldrich, Germany 
DNase I, RNase-free Fermentas, Germany 
dNTPs Fermentas, Germany 
EDTA AppliChem, Germany 
Ethanol 100% Roth, Germany 
GeneRuler 100bp DNA ladder Fermentas, Germany 
Glacial Acetic Acid Sigma Aldrich, Germany 
HEPES Sigma Aldrich, Germany 
6 × loading dye solution Fermentas, Germany 
Methylene blue Fermentas, Germany 
MgCl2 Fermentas, Germany 
M-MuLV reverse transcriptase Fermentas, Germany 
NaCl Sigma Aldrich, Germany 
Na2EDTA•2H2O Sigma Aldrich, Germany 
NaOH Sigma Aldrich, Germany 
PBS buffer PAA, Germany 
Penicillin/streptomycin PAA, Germany 
Ribonuclease inhibitor Fermentas, Germany 
RPMI 1640 medium PAA, Germany 
Sodium Citrate  Sigma Aldrich, Germany 
Taq-polymerase Fermentas, Germany 
Tris Base Sigma Aldrich, Germany 
Trypsin/EDTA Invitrogen, Germany 
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2.4. Experiment Kits 
 
CyScribe cDNA Post Labeling Kit  Amersham Biosciences, Germany 
DNeasy blood & tissue kit Invitrogen, UK 
First Strand cDNA synthesis kit Fermentas, Germany 
MessageAmp aRNA Kit Qiagen, Germany 
PCR Purification Kit Qiagen, Germany 
RNeasy mini kit Qiagen, Germany 
 
2.5. Reagents 
 
Bovine serum albumin PAA, Germany 
Fetal bovine serum (FBS) Sigma, Germany 
Penicillin/streptomycin PAA, Germany 
RPMI 1640 PAA, Germany 
 
2.6. Consumables 
 
1.5 ml Eppendorf centrifuge tubes Eppendorf, Germany 
15 ml Polypropylene tubes FALCON
®
, NJ, USA 
3.5 cm Petri dishes Roth, Germany 
25 cm
2
 T cell culture flasks Nunclon™, Denmark 
iQ 96-well PCR plates Bio-rad, USA 
96-well PCR Plate Sealing Mates Bio-rad, USA 
10 µl white tips Roth, Germany 
200 µl yellow tips Roth, Germany 
1000 µl blue tips Roth, Germany 
Distilled water Millipore, Germany 
 
2.7. Apparatus 
  
-20°C Refrigerator Bosch, Germany 
-80°C Refrigerator Bosch, Germany 
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37°C CO2 incubator Heraeus, Germany 
Coulter Counter Z2 Beckman, U.S.A 
Elekta SL-25 linear accelerator Norcross, GA 
GMS 417 arrayer MWG Biotech, Germany 
G148 microarray scanner MWG Biotech, Germany 
Heating block VWR, Germany 
iCycler Bio-Rad, USA 
Laminar flow cabinet Heraeus, Germany 
Pipettes Eppendorf, Germany 
Shaking incubators Heraeus, Germany 
Table centrifuge Heraeus, Germany 
UV spectrophotometer Bio-Rad, USA 
Water bath Lauda, Germany 
 
2.8. Buffers and medium  
 
0.5 M EDTA (pH=8) 
186.1 g Na2EDTA•2H2O (MW=372.24) 
Dissolve EDTA in 800 ml ddH2O. Adjust pH with NaOH pellets (about 20 g). Bring the 
whole volume to 1000 ml with ddH2O. Sterilize by autoclaving and store at room 
temperature. 
 
2 M HEPES 
476.6 g HEPES 
Dissolve HEPES in 800 ml ddH2O. Adjust ph with 4 N NaOH solution. Bring the final 
volume to 1000 ml with ddH2O. Store at 4°C. 
 
20 × SSC (pH= 7.0) 
175.3 g NaCl 
88.2 g Sodium Citrate (Na3C6H5O7•2H2O) 
Dissolve all the salts in 800 ml ddH2O, stir till all solid dissolved. Use a few drops of 
25% HCl to adjust the pH, and then bring the final volume to 1000 ml with ddH2O. 
Sterilize by autoclaving and store at room temperature. 
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50 × TAE Buffer (1L) 
242 g Tris Base  
57.1 ml Glacial Acetic Acid 
100 ml 0.5 M EDTA (pH=8) 
Mix Tris Base and approximately 600 ml ddH2O, stir till all solid dissolved. Add glacial 
acetic acid and EDTA solution to the mixture. Bring the whole volume to 1000 ml with 
additional ddH2O. Stir to make it even and store at room temperature. 
 
Cell culture medium 
450 ml RPMI 1640  
50 ml Fetal bovine serum (FBS) 
5 ml Penicillin/streptomycin 
Mix the three reagents together inside the clean bench and store in the 4°C. 
 
Cell frozen buffer (10 ml) 
1 ml DMSO 
2 ml FBS 
7 ml RPMI 1640 
Mix them together inside the clean bench and store at 4°C. 
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3. Methods 
3.1. Cell cultures 
3.1.1. Thawing cultured cells 
 
A549 cell line was stored in 1.8 ml freezing tubes in liquid nitrogen before use. The 
cells were thawed quickly in 37°C water bath and then transferred to a sterile 15 ml tube 
containing 5 ml preheated RPMI 1640 medium supplemented with 10% FBS and 1% 
penicillin-streptomycin. Following centrifugation at 1800 rpm for 3 min, the cells were 
resuspended in T-25 cm
2
 flask containing 5 ml preheated culturing medium. The flasks 
were incubated at 37°C in a humidified 5% CO2 atmosphere until the cells reached 
confluence.  
 
3.1.2. Trypsinizing and subculturing cells 
 
After complete aspiration of culturing medium, A549 cells were washed with PBS and 
trypsinized with 1 × trypsin-EDTA solution. Culturing medium was added into the 
flasks once all the cells were detached from the flask. Then the floating cells were 
transferred to a 15 ml centrifuge tube. Following centrifugation at 1800 rpm for 3 min, 
the cells were resuspended in fresh medium and seeded into a new flask. The medium 
was replaced 2 to 3 times per week.  
 
3.2. Radiation 
 
Cells were reseeded in 3.5 cm Petri dishes 24 hours before irradiation to gain a 
confluence of 70-80%. A549 cells were irradiated in special containers, which hold 
those culture dishes in a vertical position with the amount of cell culture medium 
needed to keep the dishes submersed. Conditioned medium was removed from the 
dishes of cell monolayers just prior to irradiation.  
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Fig.6. BIBA (Biologische Bestrahlungs-Anlage) facility in GSI, Darmstadt. 3.5 cm 
Petri dishes were placed in the magazine filled with cell culture medium, and 
irradiated in a vertical position perpendicular to the beam. 
 
Irradiation with carbon ion (9.8 MeV/nucleon on target, LET 170 KeV/μm, dose range 
from 0 to 6 Gy) and X-ray (250 kV, 16mA, dose range from 0 to 12 Gy) was performed 
at the UNILAC facility at GSI, Darmstadt, Germany. During carbon ion irradiation the 
Petri dishes were kept in a vertical position perpendicular to the beam (Fig. 6) as 
described previously (Conrad et al., 2009). Cells were reseeded in 25 cm
2
 T flasks 
immediately after irradiation and collected at different time points for further analysis.  
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3.3. Colony forming assay  
 
The RBE of high-LET radiation, such as carbon ions, is higher than that of X-ray 
(Ohnishi et al., 2004). In order to determine the biological equivalent dose between 
carbon ion and X-ray used in this study, colony forming assay was performed as 
described previously (Fournier et al., 2004). Briefly, A549 cells were trypsinized after 
irradiation and counted by Coulter Counter Z2 (Beckman, U.S.A). Samples from each 
time point and each dose were reseeded in 25cm
2
 T flasks and incubated at 37°C. The 
number of cells in each sample was determined with the respect to the planting 
efficiency and doses to obtain 100 colonies in final. After 14 days of incubation, all the 
samples were stained with Methylene blue for 10 min and observed under a microscope. 
Colonies formed by more than 50 cells were scored as survivors. All experiments were 
conducted in triplicate. 
 
3.4. Microarray analysis  
3.4.1. RNA-extraction 
 
Total RNA was extracted from frozen cell pellets using RNeasy Mint Kit (Qiagen, 
Germany) according to the manufacturer’s instructions. In brief, completely thawed cell 
pellets were disrupted by adding 350 µl buffer RLT. Then, 1 volume of 70% ethanol 
was added to homogenized lysate and together they were transferred to an RNeasy spin 
column placed in a 2 ml collection tube. After centrifuged for 15 s at 13,000 rpm, the 
flow-through was discarded. This was followed by washing once with 700 µl of buffer 
RW1, and twice with 500 µl of buffer RPE for 15 s at 13,000 rpm. The RNeasy spin 
column was replaced in a new 1.5 ml collection tube. The RNA was eluted in 50 µl of 
RNase-free water by centrifugation for 1 min at 16,000 rpm.  
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3.4.2.  Quantitative and qualitative analysis of RNA 
 
The concentration of extracted RNA was determined photometrically at λ= 260 nm. The 
absorption of 1 corresponds to 40 µg RNA/ml for normal preparations (Sambrook et al., 
1989). In addition, the A260/A280 ratio is an indication for RNA purity. Sufficiently 
pure RNA preparations showed a ratio higher than 1.8, whereas ratios lower than 1.8 
indicate contamination with protein or phenol.  
The integrity of purified RNA was checked by agarose gel electrophoresis upon 
ethidium bromide staining. The RNA samples were incubated in 37°C water bath for 1 h. 
After incubation, RNA sample were mixed with 4.5 μl of water and 1 μl of freshly 
prepared loading buffer (6 x). The sample mixture was loaded on 1% agarose gel 
contained ethidium bromide (0.5 µg/ml) and separated by electrophoresis at 80 V for 
1-2 h. The gels were then visualized under UV transillumination. 
 
3.4.3. RNA amplification 
 
In order to prepare sufficient RNA materials for array hybridization, the extracted total 
RNA samples were amplified using the MessageAmp aRNA Kit (Invitrogen, 
Huntingdon, UK) according to the manufacturer’s manual. In brief, reverse transcription 
was done with an oligo (dT) primer bearing a T7 promoter using ArrayScirpt reverse 
transcriptase to produce full-length first-strand cDNA. The cDNA samples were 
undergone with second-strand synthesis and cleanup to become the template for in vitro 
transcription. Multiple copies of RNA sample were synthezed by T7 RNA polymerase 
and followed by one step of clean up. 10 to 50 µg mRNA has be amplified from 1 µg 
total RNA after one round of in vitro transcription.  
 
3.4.4.  cDNA synthesis 
 
All RNA samples were subjected to DNase I (Fermentas, Germany) digestion for 30 
min at 37°C in order to prevent genomic DNA contamination. First strand cDNA 
synthesis was performed using cDNA synthesis kit (Fermentas, USA). Briefly, one 
microgram of total RNA was used for synthesis reaction containing 1 µl of oligo (dT)18 
primer (0.5 µg/µl) and DEPC-treated water to final volume of 11 µl and incubated at 
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70°C for 5 min. Subsequently, 4 µl of 5 × reaction buffer were added together with 1µl 
of RiboLockTM Ribonuclease inhibitor (20 u/µl). After incubation at 37°C for 5 min, 2 
µl M-MuLV Reverse Transcriptase (20 u/µl) were added to make a final volume of 20 
µl. The mixture was finally incubated at 37°C for 1 h followed by 10 min in 70°C for 
inactivation of reverse transcriptase. 
 
3.4.5. cDNA labeling 
 
The cDNA samples were labeled with Cy3 and Cy5 dyes, using the CyScribe cDNA 
Post Labeling Kit (Amersham Biosciences Europe, Freiburg, Germany). Briefly, RNA 
samples (3 mg) were reverse transcribed with nonamer primers, incorporating modified 
amino-allyl-dUTP. The synthesed cDNA was denatured with 2 µl NaOH (2.5 N) at 37°C 
for 15 min, followed by neutralization with 10 µl HEPES (2 M). The labeled cDNA 
samples were purified using PCR Purification Kit (Qiagen, Hilden, Germany) to remove 
unbound Cy dyes. 
 
3.4.6. Microarray experiments 
 
Microarray hybridizations were performed at the Institute of IMT (Molecular Biology 
and Tumor Research), Philipps-University Marburg as described previously (Berwanger 
et al., 2002). The chips used in the present study contained 11,800 clones from the 
human sequence-verified UniGene cDNA sets gf200, gf201 and gf202 
(http://www.resgen.com). Cells at 4 h after irradiation were selected as treated samples 
and compared with unirradiated cells as well as a combination of unirradiated cells, 
carbon ion (2 Gy) and X-ray (6 Gy) irradiated cells. In order to balance the different 
intensities between these two dyes, each experiment was performed as sandwich 
hybridization including reverse labeling with Cy5 and Cy3 dye for a second microarray. 
This provides a replicated measurement for each hybridization, which can be used for 
quality control and for reduction of technical variability. 
Microarrays were prehybridized for 30 min at 55°C with a blocking solution containing 
1% bovine serum albumin, 3 × SSC and 0.1% SDS. In order to reduce unspecific 
background signals, Cot1 DNA and polyA DNA were added to the labeled cDNA 
samples. The final volume of each sample loaded on the microarray chip was 100 µl, 
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including 10 µl SSC (20 ×) and 4 µl SDS (2%). Hybridized samples were boiled for 2 
min immediately before sandwich hybridization. After incubation in a humid chamber 
at 55°C for 16 h, microarray chips were separated again and washed four times 
including twice with 0.13 SSC/0.1% SDS and twice with 0.13 SSC. Finally, the chips 
were washed in water and dried by centrifugation. 
Microarray chips were scanned separately using a GMS 418 microarray scanner (MWG 
Biotech, Ebersberg, Germany). Red and green lasers were operated at 633 nm and 543 
nm to excite Cy5 and Cy3, respectively. The fluorescent data were normalized and 
analysed to calculate relative expression levels of each gene and to identify 
differentially expressed genes using the ImaGene 3.0 software (BioDiscovery Inc., 
Marina Del Rey, USA) 
 
3.5. Quantification of genes expression using qRT-PCR 
 
For calculation of relative expression of gene using 2
-ΔΔCt
 method, the amplification 
efficiencies of target and reference gene must be approximately equal (Livak et al., 
2001). Standard curves were constructed using serial dilutions of cDNA (input volume: 
0.5, 1, 2 and 2.5 µl) for selected differentially expressed genes and GAPDH.  
To validate the microarray data, qRT-PCR was performed in an iCycler (Bio-rad, USA) 
using ABsolute SYBR Green Mixes (ABgene, Germany). The primers used of selected 
differentially expressed genes were summarized in Table 1. The qRT-PCR reaction 
mixture contained 5 µl of diluted cDNA, 1.0 unit Tag-DNA polymerase, 1.5 mM MgCl2, 
0.2 mM of each dNTP, and 5 pmol of each primer with a 25 µl final volume. PCR 
reaction conditions consisted of pre-heat of 15 min at 95°C, following by 30 s at 95°C, 
30 s at anneal temperature and 45 s at 72°C for 40 cycles post initial 30 s denaturation at 
95°C, and a final extension for 2 min at 72°C. The qRT-PCR was performed in 
triplicates and included a no-template sample as a negative control. The reaction was 
evaluated by melting curve analysis after the final cycle within the range from 58-95°C. 
Relative quantification of gene expression was calculated using the 2
-ΔΔCt
 method 
(Livak et al., 2001). The mean Ct values from triplicate measurements were normalized 
to GAPDH used as internal control.  
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3.6. Functional analysis of differentially expressed genes using Faltigo 
plus and IPA 
 
The annotation and functional classification of differentially expressed genes were 
performed by using the FatiGO plus web tool as well as the Ingenuity Pathway Analysis 
(IPA) software (Ingenuity Systems, Mountain View, CA) based on the Gene Ontology 
database and the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways 
(Kanehisa, 2002, Al-Shahrour et al., 2007). The IPA classified the genes based on 
different parameters including location, molecular and biological functions, and cellular 
components. Additionally, the identified genes were categorized and mapped to genetic 
networks and signaling, metabolic and functional pathways, and ranked to determine 
their significance. The score reflects the probability that a collection of genes equal to or 
greater than the number in a network could be achieved by chance alone. According to 
the suggestion of IPA software, a cut-off score value of 3 was set in this present study. 
This score value had a 99.9% confidence level and was considered significant. 
 
3.7. Statistical analysis 
 
The association between the transcriptional expression of irradiated and unirradiated 
cells was analysed using the Students t-test with the SPSS version 15.0 software (SPSS 
Inc., Chicago, IL).The Fisher's test was used to analyse the significance of canonical 
pathways and genetic networks identified by the IPA tool. A p<0.05 was considered 
significant. 
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4. Results 
4.1. Measurement of RBE of A549 cells 
 
 
Fig. 7. Survival curves of A549 cells after irradiation with carbon ion and X-ray. 
X-axis showed the equivalent doses of carbon ion beam and X-ray. Y-axis went 
with the exponent survival rate of A549 cells. Squares represented the experiment 
points of cells irradiated with X-ray, as diamonds represented experiment points of 
cells irradiated with carbon ion beam. When at the 10% survival rate, the doses 
for carbon ion beam and X-ray were 2 Gy and 6 Gy, respectively. 
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In order to determine the biological equivalent dose between carbon ions and X-ray 
used in this study, colony forming assay was performed for the A549 cells after 
exposure to carbon beam and X-ray with different doses (Fig. 7). Carbon ions 
irradiation is slightly more effective than X-ray. According to the definition of RBE, the 
RBE10 with a survival fraction of 10% was approximately 3 with highly energy carbon 
ions. We therefore used 1/3 the physical doses of X-ray (6 Gy) for doses of carbon ion 
beams (2 Gy) in further microarray analysis. 
 
4.2. RNA quality control 
 
Because purity and integrity of RNA can have a tremendous affect on downstream 
analyses that from reverse transcription and microarray analysis to data interpretation of 
gene expression profiling, the control of RNA quality is of great importance. The purity 
and yield of RNA extracted from A549 cells were routinely determined using 
UV-spectrophotometer. Moreover, the integrity of RNA isolated was assessed by 
agarose gel electrophoresis to check for genomic DNA. As shown in Fig. 8, sharp and 
clear 28S and 18S rRNA bands are displayed in RNA samples analysed. The band of 
28S rRNA appeared to be approximately twice as intense as 18S rRNA, indicating that 
the RNA samples were intact and remained to be mostly full-length. 
36 
 
 
 
       Genomic DNA     
 
 
 
 
 
 
 
 
 
 
 
Fig. 8. Quality control of RNA by agarose gel electrophoresis. Total RNA was 
isolated from A549 cells and separated on a 1% agarose gel containing 0.5 % 
ethidium bromide. The 18S and 28S rRNA bands were clearly visible. N, 
non-irradiated; C, 2 Gy carbon ion irradiated; X, 6 Gy X-ray irradiated. 
 
4.3. Pre-processing step of microarray data analysis 
 
To examine the quality of microarray experiments, scatter plots of signal intensities 
were generated. For each spot, median signals and background intensities were obtained 
for both channels. The relationship between replicates of different samples was marked 
as a high degree of scatter and was not linear, indicating the microarray hybridizations 
were successful and could provide reliable data for further data analysis. 
28S rRNA 
18S rRNA 
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Fig.9. Scatter plots of median signal intensities of microarray data obtained from 
two channels. A showed signal intensities before normalized and without 
background correction. B showed signal intensities before normalized and with 
background correction. C showed normalized signal intensities without 
background correction. D showed normalized signal intensities with background 
correction. 
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4.4. Identification of genes regulated significantly by carbon ion beam 
radiation 
 
The gene expression profiles of A549 cells at 4 h after carbon ion (2 Gy) and X-ray (6 
Gy) irradiation were investigated using the cDNA microarray containing 11,800 gene 
transcripts. For each gene, the change in expression was calculated after carbon ion or, 
X-ray irradiation, as compared with control unirradiated cells by using the ImaGene 3.0 
software.  
Among the total of 11,800 gene transcripts, microarray analysis revealed a significant 
alterations (at least 2-fold) in the expression of 49 genes after 2 Gy carbon ion 
irradiation compared with control cells, and not affected by X-rays. Of these 
differentially expressed genes, 29 and 20 genes were up- and down-regulated, 
respectively. 
To identify differentially expressed genes induced between irradiation with carbon ion 
and X-ray, the expression profiles of A549 cells exposed to carbon ion and X-ray were 
compared. The results of microarray analysis revealed that the expression levels of 326 
genes were altered significantly (at least 2-fold) by carbon ion compared with X-rays. 
Among these genes identified, 169 were more up-regulated and 157 were 
down-regulated after carbon ion irradiation, than X-rays. 
 
4.5. Gene networks and gene ontology analyses 
4.5.1. Cellular functional classification of differently regulated genes  
 
To determine the biological relevance of these differentially expressed genes, the 
cellular functional classification of these genes were analysed using the IPA software. 
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4.5.2. Genetic network and cellular functional classification of 
differentially regulated genes induced by carbon ion irradiation 
 
In total, all of the 49 differentially expressed genes induced by carbon ions were 
mapped, and classified into genetic networks. The IPA tool delineated the involvement 
of 43 genes in 4 merged networks associated with important cellular functions (Fig. 10). 
Different molecular functions directly relevant to cancer signaling were identified i.e. 
cell cycle, cancer and cell death signaling (Table 2). Gene ontology analysis detected 
the canonical pathways with known implication in cancer (Table 3). Of these, 
statistically significant pathways such as aryl hydrocarbon receptor (AhR) signaling (p 
= 0.007) and G1/S cell cycle (p = 0.012) were identified. From these genes detected, 
CCND2, RARG and E2F5 were involved in both pathways. 
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Table 2 Merged genetic networks identified in A549 cells irradiated with carbon 
ions. 
Network Gene Function Score* 
1 Calmodulin, CAMK1D, CASP8AP2, CCND2, 
CD70, FAS, DDB2, FAIM, FGF13, GAP43, 
HBEGF, IL31, Interferon alpha, Jnk, KIF11, 
LGALS7, MAPK, NCOA7, NFkB, NRIP2, 
NUAK2, P38 MAPK, PI3K, PKMYT1, 
PPM1D, PSMC3IP, RARG, RIPK4, RNA 
polymerase II, SH2B1, THRB, TIMP3, 
TRIM32 
 
Cell Cycle, 
Hematological 
Disease, 
Gastrointestinal 
Disease 
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2 ARID1B, beta-estradiol, BTBD10, BUB1, 
C11ORF51, CDC25C, CDKN1A, CKS2, 
CKS1B, CRADD, DCTPP1, DHPS, E2F4, 
E2F5, EDN1, GHRHR, GTF2H4, KLK4, 
MIR292, MIR106A, MIRLET7B, MYC, 
NIF3L1, NPHP4, PCNA, PCTK3, PKMYT1, 
PLEKHG3, POLS, PSAP, TFDP3, TYMS, 
UBE2C, UNG, ZBED1 
 
Cell Cycle,  
Cell Signaling, 
Connective Tissue  
Development and 
Function 
19 
3 ABL1, APBA2, CDC42, CDC42BPA, 
CDC42BPB, CDC42EP1, CKS2, Cofilin, 
CTBS, EGF, ERBB, FLII, GRB2, HIST1H1B, 
HNRNPR, HRAS, hydrogen peroxide, IL5RA, 
LGALS7, LIMK2, MAPKAP1, MYC, 
NCKIPSD, OAZ2, PHKA2, PLK3, PVR, 
RCC1, RELA, RPL26, RPL21, RPL7A, 
SNRPG, Timp, UBE2C 
 
Cell Cycle,  
Cancer, Cell 
Death 
17 
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4 B3GAT3, BRE, CD70, CDC14B, CTSD, 
FAM179B, FAM40A, FGFR1OP2, HIC2, 
HTT, KCNH2, MIRN326, PDCD10, PDK2, 
PLK3, PPHLN1, PPL, PPME1, PPP1R3C, 
PPP2R1A, PPP2R2A, RP6-213H19.1, SFXN3, 
SIK1, SIKE1, STK24, STK25, STRN, STRN3, 
TAX1BP1, THRSP, TNF, TP53, TRAF3IP3, 
UBQLN2 
Cell Death,  
Amino Acid 
Metabolism, 
Molecular 
Transport 
 
19 
Network-eligible, overlapping genes (n=43) whose expression was modified after 
carbon ion irradiation but not by X-rays have been underlined. The rest of the genes 
either did not show any significant change or were not detected from the array; *A 
score>3 was significant.
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Table 3 Canonical pathways in carbon ion-irradiated genes. 
 
Ingenuity Canonical Pathways p-value 
 Aryl Hydrocarbon Receptor Signaling 0.007762 
 Cell Cycle: G1/S Checkpoint Regulation 0.012589 
 p53 Signaling 0.030903 
 Glioma Signaling 0.033884 
 Pancreatic Adenocarcinoma Signaling 0.038019 
 Hereditary Breast Cancer Signaling 0.048978 
 Lipid Antigen Presentation by CD1 0.049234 
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Fig.10. Interrelated networks of genes whose expression was modified after carbon 
ion irradiation. In total, four important networks of interrelated genes were 
identified. The four networks (green, network 1; orange, network 2; red, network 3; 
blue, network 4) were merged by overlapping genes (in bold). The degree of either 
up-regulation (red) or down-regulation (green) was reflected from the intensity of 
node color. 
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4.5.3. Genetic network of the up- and down-regulated genes between 
carbon ion and X-ray irradiation. 
 
The gene expressions varied quite differently after different irradiations. The differences 
between the numbers of genes down- or up-regulated after exposure to both irradiations 
were highly significant in several pathways, with p values (FDR of < 0.05). 
The functional analysis of the more up-regulated genes induced by carbon ion than 
X-ray determined three important functional networks involved in cellular growth and 
proliferation, cell cycle regulation, and oxidation reduction (Fig.11A-C). Of these 169 
up-regulated genes, 152 network- and functional pathway-eligible genes were mapped 
and classified into genetic networks as well as pathways (Table 4). Among the more 
down-regulated genes after carbon ion, the functional analysis identified three important 
molecular functional networks associated with cellular function and maintenance of 
cancer, regulation of cell cycle in the DNA repair and recombination, and post 
translation modification (Fig. 12A-C). Of these 157 down-regulated genes, 145 
network- and functional pathways-eligible genes were mapped and could be classified 
into functional pathways identified (Table 5). Among the transcripts significantly 
changed between carbon ion and X-ray irradiation, a number of genes was previously 
known to be radiation inducible, and another set of genes was newly identified as 
radiation regulated and was integrated in these functional networks. Several genes were 
involved in oxidation reduction (GLRX, NXN and RRM2) as well as in regulation of 
cell cycle and DNA damage response (CCND2, CDCA5, and CDC14B) were increased 
by carbon ion treatment. In contrast, a number of transcriptional regulators (BAI3, SIP1 
and SP100) was significantly decreased by carbon ion than X-ray irradiation.  
Of the molecular biological processes of these differentially expressed genes, top 
significant canonical pathways involved in important molecular functions response to 
DNA damages were identified (Table 6). 
After carbon ion beam irradiation, expression of up-regulated genes fell mostly into the 
four top canonical pathways: G2/M damage checkpoint regulation, Hedgehog signaling, 
G1/S damage checkpoint regulation, and, oxidative phosphorylation, which indicated 
the activation of DNA damage checkpoint mechanisms of individual cells stopped 
acting as part of the whole organism and focused on self repair in cells after carbon ion 
beam irradiation. The top significant canonical pathways of the more down-regulated 
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genes by carbon ion irradiation than X-ray were involved in polyamine regulation in 
cancer, VDR/RXR activation, negative regulation of cell proliferation, and cyclin in cell 
cycle regulation which indicated that carbon ion beams provoke cell cycle arrest and 
inhibit cell proliferation (Table 6). 
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Table 4. Genetic networks of up-regulated genes between carbon ion and X-ray. 
 
Network Gene Function Score* 
1 
AURKA, AURKB, BIRC5, CCNB1, CCND2, 
CDC6, CDK1, CDKN1A, CHFR, Cyclin A, 
CYFIP2, DOT1L, EED, ELAVL1, EPC1, EZH2, 
FEN1, Histone h3, Histone h4, HSPH1, ILF3, 
KCNA1, LMNB2, MYC, NCOA3, PNN, PTBP1, 
PTMA, PTRF, RNA polymerase II, RPL10A, 
RRM2, SMAD4, THRAP3, TOP2A 
 
Cellular growth  
and proliferation,  
Cellular movement 
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2 AKAP12, BIK, BTG1, CDC14A, CDC14B, 
CDT1, CEBPA, CENPE, CENPF, CSTF1, 
CUL4A, DUT, E2F4, EIF2C2, FAS, GBP1, 
H2AFX, HIPK2, HMGB3, ISG15, KLF5, 
MAD2L1, MCM6, MLH1, MPO, NEK2, PLK1, 
POLA2, PPM1D, PPP1R13B, PPP2R2B, RFC3, 
RNR, TP53, YLPM1 
 
Cell cycle regulation 
DNA Replication 
Recombination and 
Repair 
 
16 
3 ARHGEF5, BTG, CBY1, CEBPA, COX10, 
CRADD, CTNNB1, DUSP4, DUT, E2F1, GLRX, 
KLF4, MAP3K5, MPO, NEDD8, NXN, OAZ2, 
ODC1, PPP1R13B, PTGS2, RAD23A, RFC3, 
RRM2, SOD2, TMSB15A, TP53, TRD, 
YWHAH, YWHAZ 
Oxidation reduction  9 
Network-eligible, overlapping genes (n=152) whose expression was more up-regulated after 
carbon ion irradiation than X-rays have been underlined. The rest of the genes either did not 
show any significant change or were not detected from the array; *A score>3 was significant. 
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Table 5. Genetic networks of down-regulated genes between carbon ion and X-ray 
 
Network Gene Function Score* 
1 
APOH, AQP3, AURKA, AURKAIP1, CTNNB1, 
CYB5A, GNAO1, HAS2, HNF1A, HOXA5, 
HSD17B8, ISG15, KDM5B, LGALS3, 
LGALS3BP, MT1X, RARB, RARG, RXRA, 
SAT1, SCNN1A, TFRC, THBD, TP53, TSPAN7 
 
Cellular function 
and maintenance 
Cancer 
18 
2 BCL2L11, BMP4, CCL2, CCNA2, CCND3, 
CCNE2, CCNT1, CDK6, CDKN1B, CDKN2C, 
CEBPD, COPS5, DBF4, E2F1, FAS, GABPA, 
GLRX, GNAI2, GPX2, HIST4H4, HLTF, 
IFNGR1, IGF1, IGF1R, IGFBP3, MAP3K5, 
MYCN, OAZ2, SKP2, SOCS2, SP1, TOB1, 
TP63, ZNF217, ZNF616 
Cell cycle,  
Cell death,  
Recombination and 
repair 
12 
 
3 
 
APH1A, APH1B, BAI3, BLM, CCNE2, 
CDKN1A, CSTF1, CXCL1, DDB2, DHX9, 
DIO2, DUT, E2F4, H2AFX, HIST2H2BE, 
HOXA5, JUN, MCM6, NCSTN, NEK2, PLSCR1, 
PPP1R13B, PSEN2, PSENEN, RFC3, RFWD2, 
Secretase gamma, SIP1, SOD2, SP100, STMN1, 
TOPBP1, TP53, TTK, WHSC2 
 
Post translation 
modification, 
Cell cycle 
 
11 
Network-eligible, overlapping genes (n=145) whose expression was more 
down-regulated after carbon ion irradiation than X-rays have been underlined. The rest 
of the genes either did not show any significant change or were not detected from the 
array; *A score>3 was significant. 
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Table 6. Canonical pathways of the differentially expressed genes 
 
Ingenuity Canonical Pathways p-value 
 
Upregualted genes 
 Cell cycle G2/M checkpoint regulation 0.000016 
 Hedgehog Signaling 0.000105 
 Cell cycle G1/S checkpoint regulation 0.000175 
 Oxidative phosphorylation 0.000196 
  
Down-regulated genes 
 Polyamine regulation in cancer 0.000253 
 VDR/RXR activation 0.000261 
 Negative regulation of cell proliferation 0.000297 
 Cyclin in cell cycle regulation 0.000435 
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Fig.11A. Network 1 (cellular proliferation) of up-regulated genes between carbon 
ion and X-ray irradiation 
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Fig.11B. Network 2 (cell cycle regulation) of up-regulated genes between carbon 
ion and X-ray irradiation 
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Fig.11C. Network 3 (oxidation reduction) of up-regulated genes between carbon 
ion and X-ray irradiation 
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Fig.12A. Network 1 (cellular function and maintenance of cancer) of 
down-regulated genes between carbon ion and X-ray irradiation 
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Fig.12B. Network 2 (cell cycle regulation) of down-regulated genes between carbon 
ion and X-ray irradiation 
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Fig.12C. Network 3 (post translation modification) of down-regulated genes 
between carbon ion and X-ray irradiation 
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4.6. Validations of the gene expression by qRT-PCR 
4.6.1. Standard curves of primers used 
 
One of the important factors for the employment of relative qRT-PCR to validate 
microarray results is that the PCR efficiencies of the housekeeping gene and the 
candidate genes should be close to identical. In the present study, GAPDH was chosen 
as the internal standard because its widely used in study of various cancers.  
 
 
Fig.13. Determination and comparison of the qRT-PCR efficiencies of GAPDH 
and candidate (CCND2). The X-axis showed the input volume of DNA (cDNA 
synthesized directly from mRNA extracted from irradiated A549 cells, same as 
used in microarray analysis). Each point represented the mean of triplicates of 
reactions. Y-axis showed the corresponding Ct value of the DNA samples. 
Squares represent the experiment points of GAPDH, while diamonds 
represented for CCND2. 
 
The efficiencies of qRT-PCR for selected candidate genes and reference gene GAPDH 
were determined using standard curves with series dilution of input templates. 
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Representative standard curve for amplification of CCND2 and GAPDH were 
illustrated in Fig. 13.  
The straight side (dotted line) of the PCR of the referent gene GAPDH with a slope = 
-1.12 (R
2
 = 0.9368). The straight side (continuous line) of the PCR of the CCND2 
gene with a slope = -1.16 (R
2
 = 0.8995). The Ct values increase had good linear 
relationship with the quantity of input DNA and showed paralleled between candidate 
gene CCND2 and GAPDH, suggesting similar efficiencies of amplification for both 
genes analysed. Under this premise, 2
-ΔΔCt
 method can be applied in the calculation of 
the relative expression of genes. 
 
4.6.2. Expression levels of irradiated genes  
 
To validate the consistency and reproducibility of microarray experiments, a subset of 
8 differentially expressed genes involved in cell cycle, DNA damage and transcription 
were analysed by qRT-PCR. The cellular functions of the selected genes are 
summarized in Table 7. Expression levels were normalized with the housekeeping 
gene GAPDH and calculated as fold change value of irradiated cell versus 
unirradiated control.  
Among these 8 genes analysed, CDKN1A was up-regulated at 4 h by both irradiations 
with carbon ion and X-ray. Use of qRT-PCR analysis, we confirmed the up-regulation 
of cell cycle related genes CCND2, CDCA5, CDC14B, as well as E2F5, which are 
involved in promoting of transcription and proliferation of cell. Carbon ion irradiation 
showed significant effects on the expression of these 4 genes than X-ray. In contrast, 
the expression level of CDC25B, TP53I11 and RARG decreased more effectively 
after X-ray than carbon ion irradiation (Figure 14).  
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Table 7. Functions of genes selected for the validation of microarray results. 
Gene symbol Gene name Function 
CCND2 cyclin D2 cell cycle 
CDCA5 cell division cycle associated 5 cell cycle 
CDC14B cell division cycle 14 homolog B DNA damage, cell division 
CDC25B cell division cycle 25 homolog B DNA damage, cell division 
CDKN1A cyclin-dependent kinase inhibitor 1A, p21 cell cycle, DNA damage 
E2F5 transcription factor 5, p130-binding transcription, proliferation 
RARG retinoic acid receptor, gamma transcription 
TP53I11 tumor protein p53 inducible protein 11 DNA damage, transcription  
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Fig.14. Validation of selected genes in A549 cells 4 h after carbon ion beam and 
X-ray irradiation using qRT-PCR. The qRT-PCR results of transcriptional 
expression were normalized to the values of GAPDH gene and then expressed as 
fold in comparison to unirradiated, control cells (0 Gy). Data were expressed as 
mean ± SD. * p < 0.05 using Student’s test for comparison between carbon ion 
and X-ray irradiation.  
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5. Discussion 
 
In this study, the gene expression profiles were investigated in lung adenocarcinoma 
cell A549 after irradiation with carbon ion and X-ray. The differently expressed genes 
with their functional categories and biological pathways associated with carbon ion 
induced DNA-damages were analysed using web-based transcriptional networks. 
Changes in transcriptional expression of selected differently expressed genes involved 
in important cellular functions response to DNA damages were assessed by qRT-PCR. 
The identification of different expression changes suggested different effects on gene 
expressions between carbon ions and X-ray and might contribute to a better 
understanding of the molecular response to carbon ion irradiation in lung cancer cells. 
 
5.1. Increased RBE of carbon ion on A549 cells 
 
Due to its superior physical and biological characterizations, heavy ion beams can 
induce highly complex clustered DNA damages resulting in increased biologic effects 
(Hamada, 2009). Previous experimental data demonstrated that heavy ions including 
carbon ion are more effective on cell killing than X-ray (Cox et al., 1977, Goodhead 
et al. 1993). The increased RBE represents one of the major rationales for the 
application of heavy ions in tumor therapy. Blakely et al. (1979) reported that the 
RBE values of T-1 kidney cells were about 1.2 for 13-KeV/μm and 2.3 for 
85-KeV/μm carbon beams. However, different types of ion beams with similar LET 
values resulted in different cell killing effects, indicating that biological effects caused 
by heavy ions strongly associated with the characters of ion beams (Fokas E et al., 
2009). Following carbon ion (29 KeV/μm) exposure, an enhanced frequency of 
apoptotic cells and an increase in aberrant cells were observed in human 
hematopoietic stem and progenitor cells, resulting in a RBE of 1.4-1.7 compared with 
X-ray (Becker et al., 2009). Suzuki et al. (2000) in Chiba, Japan have systematic 
analysed 14 tumor cell lines exposed to carbon ions with two different LET values. 
The reported RBE values were 1.06-1.33 for 13 KeV/μm and 2.00-3.01 for 77 
KeV/μm carbon beams. These studies have provided the RBE values of many types of 
normal and carcinoma cells and suggested that the increased RBE associated with 
increasing LET values of ion beams (Suzuki et al., 2000; Sørensen et al., 2011). In the 
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present study, we assessed the RBE of A549 cells irradiated with high LET carbon 
beams (170 KeV/μm), an energy of carbon ions routinely used in the GSI (Fournier et 
al., 2004). In line with previous report using carbon ions with lower LET values (13.3 
and 77 KeV/μm), an enhanced RBE value for high LET carbon beams was detected in 
present study, suggesting the LET dependence of cell killing effect.  
 
5.2. Gene expression profiling changes differently between X-ray and 
carbon ion radiations 
 
Experimental studies in vitro and in vivo demonstrated differences in the regulation of 
cell cycle, DNA repair, angiogenesis and apoptosis on normal epithelia und carcinoma 
cells between photon- and heavy ion irradiation. However, few studies have 
investigated genetic aberrations and gene expression induced by heavy ion irradiation. 
The molecular mechanisms and the signaling pathways involved in cellular responses 
to heavy ion radiation are not completely understood. 
Kurpinski et al. (2009) compared the biological effects of 
56
Fe ions and X-ray on 
human mesenchymal stem cells and found distinct differential transcriptional 
regulation associated with more significant effects of 
56
Fe ions on DNA/RNA 
metabolism, cell cycle regulation and DNA-binding activity using an Affymetrix 
microarray containing 22,277 probe-sets. Using a cDNA expression array containing 
161 genes of DNA damage and repair signaling pathway, Roy et al. (2008) examined 
the gene expression profiling of breast epithelial cell MCF-10F exposed to lower 
doses of 
56
Fe ions and X-ray. Of the 161 genes analysed, 30 and 16 genes were altered 
by X-ray and 
56
Fe ions, respectively. Two recent studies on OSCC in Chiba, Japan 
have showed that 98 genes were induced significantly by carbon ion irradiation at all 
dose points in the three OSCC cell lines compared with unirradiated control cells 
(Higo et al., 2006, Fushimi et al., 2008).  
Moreover, Akino et al. (2009) have showed the effect of carbon ion beam on the 
aggressiveness and gene expression of A549 cell and identified 23 and 22 up- and 
down regulated genes after carbon ion irradiation using PCR technology. Although 
these studies analysed different cells exposed to different heavy ions with different 
LET, the observations in these studies as well as our results in this study demonstrated 
special changes in gene expression induced by heavy ions and provided preliminary 
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evidence linking alterations in global gene expression and changes in cellular 
responses after heavy ions irradiation.  
 
5.3. Signaling pathways of different expressed genes between carbon 
ion irradiation and X-ray  
 
The pathway analysis of the up-regulated genes between carbon ion and X-ray 
irradiation in this study have showed that mostly overrepresented biological processes 
of these genes were cell proliferation and oxidation reduction by using the IPA 
pathway tool. Tumor hypoxia is a well-recognized factor contributing to tumor 
progress, angiogenesis and genetic instability (Denko NC., 2008). Radiation 
generated reactive oxygen species lead to formation of DNA lesions such as DSBs 
and act as the principal determinants of cell killing (Dewhirst et al., 2008). However, 
high-LET irradiation induces clustered DNA damage that is much less dependent on 
the formation of reactive oxygen species for cell killing than X-ray, since OER 
decreases with increasing LET (Curtis et al., 1984). Several genes such as GLRX, 
NXN and RRM2, involved in the oxidation and reduction were found to be altered 
after carbon ions irradiation in this study. The enzyme glutaredoxin (GLRX) can 
inhibit NFkB survival pathway and promote apoptosis in hypoxic cancer cells 
(Qanungo et al., 2007). NXN is reactive oxygen species regulator involved in cell 
growth and differentiation. Expression of NRN can inhibit Wnt pathway and lead to 
promote apoptosis and enhance radiosensitization in cancer stem cells (Chen et al., 
2007; Funato Y et al., 2008). The ribonucleotide reductase subunit RRM2 is essential 
for DNA synthesis. Activation of RRM2 by an ATR/ATM-CHK1-E2F1 pathway is 
implicated in the regulation of cell cycle and DNA repair after DNA damage (Zhang 
et al., 2009). Experimental data in vivo and clinical results have demonstrated that 
heavy ion therapy reduces hypoxia-driven tumor radioresistance (Furusawa et al., 
2000). The enhanced induction of these genes involved in oxidation reduction and cell 
proliferation after carbon ion radiation in this study suggested that the activation of 
these pathways may be differently regulated between carbon ion and X-ray radiation. 
 
Experimental findings from both synchronous and asynchronous cell populations 
have found that heavy ion irradiation induced more pronounced G1-phase and 
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prolonged G2/M-phase delay, which could account for the increased effectiveness of 
heavy ions compared with X-rays. (Scholz et al., 1994, Goto et al., 2002, Nasonova et 
al., 2004). Our functional network analysis revealed that the down regulated genes 
between carbon ion and X-ray irradiation were mainly involved in cell mitosis, cell 
cycles and division. Critical transitions in the different phases of the cell cycle are 
regulated by sequential activation of cyclins and their catalytic subunits, the 
cyclin-dependent kinases (Malumbres et al., 2009). In response to DNA damage such 
as irradiation, the suppression of CDKs and the activation of CDK inhibitors induce 
cell cycle delay or arrest to allow time for either the repair of DNA damage or the 
elimination of genetically unstable cells by apoptosis (Jeggo et al., 2006). In the 
present study, we found down-regulation of CDK1, CCNB1 and CDC25B and 
up-regulation of CDK inhibitor p21, are more responsible to carbon ions than X-ray. 
The CDK inhibitor p21 plays key roles in DNA-damage responses such as cell cycle 
checkpoints, senescence, and apoptosis (Abbas T and Dutta A, 2009). Precious studies 
on fibroblasts as well as cancer cells have found that heavy-ion traversal (calcium and 
carbon ions) formed p21 foci, that resembled extremely the pattern of charged 
particles and persisted for several hours, in contrast to X-rays where a short-lived, 
diffusely spread pattern was observed (Jacob et al., 2002; Fournier C et al., 2004; 
Koike et al., 2011). Irradiation with carbon ion with varying LET values (300 to 13600 
KeV/μm) revealed a strict spatial correlation for the occurrence of CDKN1A and 
PCNA with MRE11B clusters as well as of CDKN1A with gamma-H2AX signals 
(Jakob et al., 2003). These findings suggested that the alterations of these repair genes 
might lead to less efficient rejoining of G1 and G2 DNA breaks, less repair and 
subsequently higher numbers of residual breaks induced by high-LET irradiation with 
carbon ions. In line with these observations, the alterations in expression of cell cycle 
regulators in the present study may, at least in part contribute to prolonged cell cycles 
delay in heavy ion irradiated cells.  
 
Although the introduction of microarray technology is a great-leap-forward 
development in genomic variations of various tumor subtypes both experimentally 
and clinically, their high price and limitation of inter-study comparability hampered 
their widespread application. Therefore, quantitative real time polymerase chain 
reaction (qRT-PCR), as the most sensitive technique currently available for detection 
and quantification of gene expression, become the most suitable and powerful 
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complement arrays for the conformation and validation of individual transcripts in 
lager sample cohorts.  
Basic research from biophysics and radiobiology has lead to new, promising 
perspectives in particle therapy. The significant differences in radiobiology of heavy 
ions beams from the conventional photon radiobiology should be further studied for 
the benefit of cancer patients. Additional functional studies of the differently 
expressed genes identified in this study may clarify and extend the importance of 
these genes in the regulation of DNA damage after carbon ion radiation in lung cancer 
cells. 
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6. Future prospects 
 
Carbon ions irradiation provides both physical and biological advantages and is 
promising for the treatment of NSCLC regarding local control and overall survival. 
Carbon ions can cause clustered DNA damage and lead to induction of transcriptional 
programs and activation of DNA damage response pathways. Our data in this study 
show different expression profiles in lung cancer cells irradiated with carbon ions and 
X-ray using high-density cDNA microarray and identify a set of differentially 
expressed genes. The functional classification of these differentially expressed genes 
suggests the involvement in important signaling pathways such as the regulation of 
cell cycle, DNA repair and oxidation and reduction. Understanding the molecular 
mechanisms underlying cellular response of carbon ions will certainly have an impact 
on numerous field of radiation therapy. Future experiments are needed to examine the 
functions of these genes in detail and will provide insights into their role in lung 
cancer cells exposed to carbon ions. 
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7. Summary 
 
Background 
Lung cancer is the leading cause of cancer-related death in men and the third in 
women in Germany. Radiation therapy plays an important role in the multimodal 
treatment of lung cancer. Due to the excellent dose distribution and the higher relative 
biological effectiveness (RBE) in tumor, heavy ion therapy with carbon shows 
promising clinical results in different types of cancer. However, the genetic 
differences of radiation induced reactions in cancer between heavy ion beams and 
conventional photon beams are not fully understood. In the present study, we 
compared the gene expression profiles of A549 cells after heavy ion radiation or 
X-ray radiation using a DNA microarray chip containing 11,800 human genes and 
identified differentially expressed genes. A set of selected differentially expressed 
genes was validated with quantitative real-time polymerase chain reaction 
(qRT-PCR). 
 
Materials/Methods 
The lung carcinoma cell line A549 was irradiated with carbon ion beams (9,8 
MeV/nucleon) and X-ray (250 kV) using different doses. The biologically equivalent 
doses for each radiation quality were determined by clonogenic survival assay. The 
transcriptional profiling was determined with a high density cDNA microarray 
containing 11.800 genes, and genetic network and gene ontology analysis was 
performed. The expression changes of selected genes were validated by qRT-PCR. 
 
Results 
Microarray analysis revealed a significant alteration in the expression of 49 genes (at 
least 2-fold) after carbon ion irradiation and not altered by X-rays, as compared with 
unirradiated control cells. Of these 49 differentially expressed genes identified, 29 and 
20 genes were up- and down-regulated, respectively. 
Moreover, the results of microarray analysis showed that the expression levels of 326 
genes were altered significantly by carbon ion irradiation with biological equivalent 
dose to X-rays. Among these genes identified, 169 and 157 genes were more up-and 
down-regulated in carbon ion irradiation, as compared to X-rays. 
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The genetic network and functional classification of the 49 differentially expressed 
genes between carbon ions irradiation and control unirradiated cells revealed four 
merged networks which were associated with the regulation of cell cycle, cancer and 
cell death signaling and cell signaling.  
The functional analysis of the up-regulated genes between carbon ion and X-ray 
determined three important functional networks involved in cellular growth and 
proliferation, cell cycle regulation, and oxidation reduction. Among the 
down-regulated genes, the functional analysis identified three important molecular 
functional networks associated with cellular function and maintenance of cancer, 
regulation of cell cycle in the DNA repair, and post translation modification. A set of 8 
selected differentially expressed genes involved in cell cycle, DNA damage and 
transcription was analysed by qRT-PCR and confirmed the microarray data.  
 
Conclusions 
These results showed that these two types of radiations, although in the same 
biological relative doses, could induce significant gene expression in different levels 
in A549 cells. The functional classification of these differentially expressed genes 
revealed that carbon ions and X-ray irradiations have different effects on different 
signaling pathways through gene expression. The identification of differentially 
expressed gene in this study might add to the understanding of the complicated 
molecular responses to carbon ion irradiation and provided valuable resource for both 
experimental and clinical application of heavy ion beam for treatment of lung cancer. 
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7. Zusammenfassung 
 
Das Lungenkarzinom ist die häufigste tödliche Krebserkrankung des Mannes und die 
dritthäufigste tödliche Krebserkrankung der Frau in Deutschland. Die 
Strahlentherapie spielt eine wichtige Rolle in der multimodalen Behandlung vom 
Lungenkarzinom. Aufgrund der hervorragenden Dosisverteilung und der höheren 
relativen biologischen Wirksamkeit (RBW) im Tumor  zeigt die 
Schwerionentherapie mit Kohlenstoff vielversprechende klinische Ergebnisse bei 
unterschiedlichen Karzinomen. Die genetischen Unterschiede der Strahlenreaktionen 
im Krebsgewebe nach intensiver Ionenbestrahlung und konventioneller 
Photonenbestrahlung sind aber bis heute nicht vollständig geklärt. In der vorliegenden 
Arbeit wurden deshalb die Expressionsprofilen humaner A549 Lungenkarzinomzellen 
nach Bestrahlung mit Kohlenstoffionen und Röntgenstrahlen mittels eines cDNA 
Microarrays mit 11.800 menschlichen Genen verglichen und differentiell exprimierten 
Gene identifiziert. Mit quantitativer Real-Time PCR (qRT-PCR) wurden die 
Veränderungen der ausgewählten differentiell exprimierten Kandidatengene 
analysiert. 
 
Die A549 Lungenkarzinomzellen wurden mit Kohlenstoffionen (9,8 MeV/nucleon) 
und Röntgen (250 kV) bestrahlt. Die biologischen Äquivalentdosen der 
Kohlenstoffionen und Röntgenstrahlen wurden mit dem klonogenen Überleben-Assay 
bestimmt.  
 
Im Vergleich zur unbestrahlten Kontrolle zeigte die Mikroarray-Analyse signifikante 
Veränderungen der Expression von 49 Genen (mindestens 2-fach) nach Bestrahlung 
mit Kohlenstoff. Davon waren 29 Gene und 20 Gene hoch- und runterreguliert. 
Anhand der Analyse der Expressionsprofile konnten 326 differentiell exprimierten 
Gene zwischen Bestrahlung mit Kohlenstoffionen und Röntgenstahlen mit den 
biologischen Äquivalentdosen identifiziert werden. Im Vergleich zur 
Röntgenstrahlung waren 169 bzw. 157 Gene nach Bestrahlung mit Kohlenstoffionen 
signifikanter hoch- und runterreguliert. Die genetische Netzwerk und funktionelle 
Klassifizierungen der 49 differentiell exprimierten Gene zwischen 
Kohlenstoffionenstrahlung und unbestrahlter Kontrolle zeigten vier fusionierten 
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Netzwerke, welche in der Regulation des Zellzykluses, des Zelltods, und des 
Zellsignalwegs beteiligt sind. Weitere funktionelle Analyse der hochregulierten Gene 
zwischen Kohlenstoffionen und Röntgenstahlen zeigte drei wichtige funktionelle 
Netzwerke, welche an der Regulation der zellulären Proliferation, des Zellzykluses 
und der Oxidation beteiligt sind. Die Analyse der runterregulierten Gene zeigte drei 
wichtige molekulare funktionelle Netzwerke in der Regulation der zellulären 
Funktion and der Erhaltung des Karzinoms, des Zellzykluses mit der DNA-Reparatur 
und der posttranskriptionellen Modifizierung. Zur Bestätigung der Mikroarraydaten 
wurde die Expression der 8 ausgewählten differentiell exprimierten Kandidatengene, 
welche an der Regulation des Zellzykluses, der DNA-Schädigung und der 
Transkription beteiligt sind, durch qRT-PCR analysiert. 
 
Die Ergebnisse der vorliegenden Arbeit deuteten darauf hin, dass beide 
Strahlenqualitäten mit biologischen Äquivalentdosen signifikante unterschiedliche 
Genexpressionen induzieren und dadurch die unterschiedlichen Wirkungen auf der 
Regulation der Signaltransduktionswege beeinflussen konnten. Die differentiell 
expremierten Gene sind an der Regulation der Zellzyklen, DNA-Reparatur und der 
Oxidierung beteiligt. Die Identifizierung der differentiell exprimierten Gene in der 
vorliegenden Arbeit kann zum Verständnis der komplizierten molekularen Reaktionen 
auf Bestrahlung mit Kohlenstoffionen hinzufügen und wertvolle Ressource sowohl 
für experimentelle als auch für klinische Anwendung der Schwerionentherapie von 
Lungenkarzinom zur Verfügung stehen. 
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9.3.  Genes significantly up-regulated by carbon ion beam irradiation 
 
Symbol 
Entrez 
Gene ID 
Gene Name 
ABCC5 10057 ATP-binding cassette, sub-family C (CFTR/MRP), 
member 5  
APBA2 321 amyloid beta (A4) precursor protein-binding, family 
A, member 2  
B3GAT3 26229 beta-1,3-glucuronyltransferase 3 
(glucuronosyltransferase I)  
C11ORF51 25906 chromosome 11 open reading frame 51  
CAMK1D 57118 calcium/calmodulin-dependent protein kinase ID 
CCND2 894 cyclin D2 
CD70 970 CD70 molecule 
CDC14B 8555 CDC14 cell division cycle 14 homolog B  
CDC42EP1 11135 CDC42 effector protein (Rho GTPase binding) 1  
CTBS 1486 chitobiase, di-N-acetyl 
DDB2 1643 damage-specific DNA binding protein 2 
DHPS 1725 deoxyhypusine synthase 
E2F5 1875 E2F transcription factor 5, p130-binding  
FAM179B 23116 family with sequence similarity 179, member B  
GAP43 2596 growth associated protein 43  
HBEGF  1839 heparin-binding EGF-like growth factor  
HIC2 23119 hypermethylated in cancer 2  
HNRNPR 10236 heterogeneous nuclear ribonucleoprotein R  
HPS1 3257 Hermansky-Pudlak syndrome 1  
PLEKHG3 26030 pleckstrin homology domain containing, family G 
(with RhoGef domain) member 3  
POLS 11044 PAP-associated domain-containing protein 7 
PPHLN1 51535 periphilin 1  
RNF219 79596 ring finger protein 219  
SFXN3 81855 sideroflexin 3  
THRB 7068 thyroid hormone receptor, beta  
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TIMP 7076 TIMP metallopeptidase inhibitor 1 
TIMP3 7078 TIMP metallopeptidase inhibitor 3 
TRIM32 22954 tripartite motif containing 32  
APBA2 321 amyloid beta (A4) precursor protein-binding, family 
A, member 2  
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9.4. Genes significantly down-regulated by carbon ion beam 
irradiation 
 
Symbol 
Entrez Gene 
ID 
Gene Name 
BTBD10 84280 BTB (POZ) domain containing 10  
C9ORF75 286262 chromosome 9 open reading frame 75  
CDC42BPA 8476 
CDC42 binding protein kinase alpha 
(DMPK-like)  
DCTPP1 79077 dCTP pyrophosphatase 1  
FGFR1OP2 26127 FGFR1 oncogene partner 2  
NPHP4 261734 nephronophthisis 4  
OAZ2 4947 ornithine decarboxylase antizyme 2  
PHKA2 5256 phosphorylase kinase, alpha 2 (liver)  
PPM1D 8493 
protein phosphatase, Mg2+/Mn2+ 
dependent, 1D  
PPME1 51400 protein phosphatase methylesterase 1  
OAZ2 4947 ornithine decarboxylase antizyme 2  
PCTK3 5129 PTCTAIRE-motif protein kinase 3 
RARG 5916 retinoic acid receptor, gamma  
RIPK4 54101 
receptor-interacting serine-threonine 
kinase 4  
RPL21 6144 ribosomal protein L21  
SH2B1 25970 SH2B adaptor protein 1  
SNRPG 6637 
small nuclear ribonucleoprotein 
polypeptide G  
SYDE1 85360 
synapse defective 1, Rho GTPase, 
homolog 1 (C. elegans)  
TAX1BP1 8887 
Tax1 (human T-cell leukemia virus type 
I) binding protein 1  
TSPAN17 26262 tetraspanin 17  
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9.5. List of genes up-regulated by carbon ion beam irradiation 
compared to X-ray 
 
Symbol Entrez Gene ID Gene Name     
ABCF2 10061 ATP-binding cassette, sub-family F, member 2  
ACLY 47 ATP citrate lyase  
ACTA2 59 Actin, alpha 2, smooth muscle, aorta  
ACTG2 72 Actin, gamma 2, smooth muscle, enteric  
ADAM11 4185 ADAM metallopeptidase domain 11  
ADAM15 8751 ADAM metallopeptidase domain 15  
AFAP1 60312 Actin filament associated protein 1  
AGAP2 116986 ArfGAP with GTPase domain 
AMOTL2 51421 Angiomotin like 2  
ANKRA2 57763 Ankyrin repeat, family A (RFXANK-like), 2  
ANXA5 308 Annexin A5  
ASB1 51665 Ankyrin repeat and SOCS box-containing 1  
ASXL1 171023 Additional sex combs like 1  
ATP2B3 492 ATPase, Ca++ transporting, plasma membrane 3 
ATP5G2 517 ATP synthase, mitochondrial Fo complex, subunit C2 
AURKA 6790 Aurora kinase A  
AURKB 9212 Aurora kinase B  
AUTS2 26053 Autism susceptibility candidate 2   
BGN 633 Biglycan   
BIRC5 332 Baculoviral IAP repeat-containing 5 (survivin)  
BMS1 9790 BMS1 homolog, ribosome assembly protein  
CACYBP 27101 Calcyclin binding protein  
CAMSAP1 157922 Calmodulin regulated spectrin-associated protein 1 
CAMSAP1L1 23271 Calmodulin regulated spectrin-associated protein 
1-like 1 
CCDC43 124808 Coiled-coil domain containing 43  
CCNB1 891 Cyclin B1  
CCND2 894 cyclin D2  
CCT4 10575 Chaperonin containing TCP1, subunit 4 (delta)  
93 
 
CDC14B 8555 CDC14 cell division cycle 14 homolog B  
CDC2 983 Cell division cycle 2, G1 to S and G2 to M  
CDC6 990 Cell division cycle 6 homolog (S. cerevisiae)  
CDCA5 113130 Cell division cycle associated 5  
CDKN1A 1026 Cyclin-dependent kinase inhibitor 1A (p21)  
CENPF 1063 Centromere protein F, 350/400ka (mitosin)  
CHAF1B 8208 Chromatin assembly factor 1, subunit B (p60)  
COTL1 23406 Coactosin-like 1 (Dictyostelium)  
COX10 1352 Cytochrome c oxidase assembly protein  
CPSF6 11052 Cleavage and polyadenylation specific factor 6, 
68kDa 
CTPS 1503 CTP synthase  
CUL4A 8451 Cullin 4A  
CYB5R4 51167 Cytochrome b5 reductase 4  
CYFIP2 26999 Cytoplasmic FMR1 interacting protein 2   
DCUN1D5 84259 DCN1, defective in cullin neddylation 1, domain 
containing 5  
(S. cerevisiae) 
DDEF1 50807 Development and differentiation enhancing factor 1 
DDX41 51428 DEAD (Asp-Glu-Ala-Asp) box polypeptide 41  
DDX46 9879 DEAD (Asp-Glu-Ala-Asp) box polypeptide 46  
DHX8 1659 DEAH (Asp-Glu-Ala-His) box polypeptide 8  
DKC1 1736 Dyskeratosis congenita 1, dyskerin  
DTYMK 1841 Deoxythymidylate kinase (thymidylate kinase) 
E2F5 1875 E2F transcription factor 5  
EED 8726 Embryonic ectoderm development  
EIF2C2 27161 Eukaryotic translation initiation factor 2C, 2   
ELAV 1994  (embryonic lethal, abnormal vision, Drosophila)-like 
1  
EMP2 2013 Epithelial membrane protein 2  
EPC1 80314 Enhancer of polycomb homolog 1 (Drosophila) 
EPHB6 2051 EPH receptor B6   
EYA2 2139 Eyes absent homolog 2 (Drosophila)  
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EZH2 2146 Enhancer of zeste homolog 2 (Drosophila)  
FAM43A 131583 Family with sequence similarity 43, member A  
FAM44B 91272 Family with sequence similarity 44, member B 
FAM83D 81610 Family with sequence similarity 83, member D  
FAM84A 151354 Family with sequence similarity 84, member A  
FARP1 10160 FERM, RhoGEF and pleckstrin domain protein 1  
FARSA 2193 Phenylalanyl-tRNA synthetase, alpha subunit  
FAS 355 Fas (TNF receptor superfamily, member 6)   
FEN1 2237 Flap structure-specific endonuclease 1  
FEZ2 9637 Fasciculation and elongation protein zeta 2 (zygin II) 
FGFR1 2260 Fibroblast growth factor receptor 1 (fms-related 
tyrosine kinase 2, Pfeiffer syndrome) 
FJX1 24147 Four jointed box 1   
FLNA 2316 Filamin A, alpha   
GALNT13 114805 UDP-N-acetyl-alpha-D-galactosamine:polypeptide 
N-acetylgalactosaminyltransferase 13  
GDAP1 54332 Ganglioside-induced differentiation-associated 
protein 1  
GEM 2669 GTP binding protein overexpressed in skeletal muscle 
GLDC 2731 Glycine dehydrogenase (decarboxylating)  
GPR116 221395 G protein-coupled receptor 116  
GTPBP4 23560 GTP binding protein 4  
H2AFX 3014 H2A histone family, member X  
HEATR2 54919 HEAT repeat containing 2  
HERC4 26091 Hect domain and RLD 4  
HIPK2 28996 Homeodomain interacting protein kinase 2  
HMGB3 3149 High-mobility group box 3  
HNRNPU 3192 Heterogeneous nuclear ribonucleoprotein U  
HSPB8 26353 Heat shock 22kDa protein 8   
HSPH1 10808 Heat shock 105kDa/110kDa protein 1  
IFT88 8100 Intraflagellar transport 88 homolog (Chlamydomonas) 
ILF3 3609 Interleukin enhancer binding factor 3, 90kDa  
KCNA1 3736 Potassium voltage-gated channel, shaker-related 
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subfamily, member 1 
KDM2A 22992 Lysine (K)-specific demethylase 2A   
KLK10 5655 Kallikrein-related peptidase 10   
KNTC1 9735 Kinetochore associated 1  
KRT7 3855 Keratin 7  
LMNB2 84823 Lamin B2  
LSM14A 26065 SCD6 homolog A  
MAD2L1 4085 MAD2 mitotic arrest deficient-like 1  
MAMLD1 10046 Mastermind-like domain containing 1   
MAPRE1 22919 Microtubule-associated protein, RP/EB family, 
member 1 
MBNL3 55796 Muscleblind-like 3 (Drosophila)   
MPO 4353 Myeloperoxidase  
MYC 4609 V-myc myelocytomatosis viral oncogene homolog 
(avian) 
NCAPH 23397 Non-SMC condensin I complex, subunit H  
NCOA3 8202 Nuclear receptor coactivator 3  
NEK6 10783 NIMA (never in mitosis gene a)-related kinase 6 
NET1 10276 Neuroepithelial cell transforming gene 1  
NUDT13 2596 Nudix -type motif 13   
NUP85 79902 Nucleoporin 85kDa  
NUP93 9688 Nucleoporin 93kDa  
NXN 64359 Nucleoredoxin  
ODC1 4953 Ornithine decarboxylase 1  
OLFML2A 169611 Olfactomedin-like 2A  
PAH 5053 Phenylalanine hydroxylase   
PDXP 57026 Pyridoxal (pyridoxine, vitamin B6) phosphatase 
PLEKHG3 26030 Pleckstrin homology domain containing, family G, 
member 3 
PLK1 5347 Polo-like kinase 1   
PNN 5411 Pinin, desmosome associated protein  
POLA2 23649 Polymerase (DNA directed), alpha 2 (70kD subunit) 
PPM1D 8493 Protein phosphatase 1D magnesium-dependent, delta 
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isoform 
PPP1R14A 94274 Protein phosphatase 1, regulatory (inhibitor) subunit 
14A 
PRKAG2 51422 Protein kinase, AMP-activated, gamma 2 
non-catalytic subunit 
PRKAR1A 5573 Protein kinase 
alpha (tissue specific extinguisher 1) 
PRSS23 11098 Protease, serine, 23  
PSMD12 5718 Proteasome, 26S subunit, non-ATPase, 12 
PSPC1 55269 Paraspeckle component 1  
PTBP1 5725 Polypyrimidine tract binding protein 1  
PTPRJ 5795 Protein tyrosine phosphatase, receptor type, J 
PTRF 284119 Polymerase I and transcript release factor  
RAD18 56852 RAD18 homolog (S. cerevisiae)  
RAMP1 10267 Receptor (G protein-coupled) activity modifying 
protein 1 
RARRES3 5920 Retinoic acid receptor responder 3   
RBM14 10432 RNA binding motif protein 14  
RBM3 5935 RNA binding motif (RNP1, RRM) protein 3  
REV1 51455 REV1 homolog  
RFC4 5984 Replication factor C (activator 1) 4, 37kDa  
RPIA 22934 Ribose 5-phosphate isomerase A  
RRM2 6241 Ribonucleotide reductase M2 polypeptide  
RSU1 6251 Ras suppressor protein 1  
SAE2 10054 SUMO1 activating enzyme subunit 2  
SDCCAG3 10807 Serologically defined colon cancer antigen 3  
SESN3 143686 Sestrin 3   
SF1 7536 Splicing factor 1  
SF3B5 83443 Splicing factor 3b, subunit 5, 10kDa  
SFRP1 6422 Secreted frizzled-related protein 1   
SFRS2B 10929 Splicing factor, arginine/serine-rich 2B  
SLC26A2 1836 Solute carrier family 26 (sulfate transporter), member 
2 
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SLC31A2 1318 Solute carrier family 31 (copper transporters), 
member 2 
SLC6A16 28968 Solute carrier family 6, member 16   
SLC7A5 8140 Solute carrier family 7 (cationic amino acid 
transporter), member 5 
SMAD4 4089 SMAD family member 4   
SRR 63826 Serine racemase  
STX2 2054 Syntaxin 2  
SYDE1 85360 Synapse defective 1, Rho GTPase, homolog 1 (C. 
elegans) 
SYNCRIP 10492 Synaptotagmin binding, cytoplasmic RNA interacting 
protein 
TARDBP 23435 TAR DNA binding protein  
TAX1BP3 30851 Tax1 (human T-cell leukemia virus type I) binding 
protein 3 
TMEPAI 56937 Transmembrane, prostate androgen induced RNA 
TNS3 64759 Tensin 3   
TOM1 10043 Target of myb1 (chicken)  
TOP2A 7153 Topoisomerase (DNA) II alpha 170kDa   
TRIM15 89870 Tripartite motif-containing 15   
TSFM 10102 Ts translation elongation factor, mitochondrial  
TSPAN15 23555 Tetraspanin 15  
TUBGCP3 10426 Tubulin, gamma complex associated protein 3 
TXNDC1 81542 Thioredoxin domain containing 1  
UBE2G1 7326 ubiquitin-conjugating enzyme E2G 1  
WDR57 9410 WD repeat domain 57 (U5 snRNP specific)  
WDR77 79084 WD repeat domain 77  
YLPM1 56252 YLP motif containing 1  
YWHAH 7533 Tyrosine 3-monooxygenase/tryptophan 
5-monooxygenase activation protein, eta polypeptide 
YWHAZ 7534 Tyrosine 3-monooxygenase/tryptophan 
5-monooxygenase activation protein, zeta polypeptide 
ZFAND5 7763 Zinc finger, AN1-type domain 5   
98 
 
ZNF30 90075 Zinc finger protein 30  
ZNF532 55205 Zinc finger protein 532  
ZWILCH 55055 Zwilch, kinetochore associated, homolog 
(Drosophila) 
ZXDC 79364 ZXD family zinc finger C  
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9.6.  List of genes down-regulated by carbon ion beam irradiation 
compared to X-ray 
 
Symbol Entrez Gene ID Gene Name 
ACOX1 51 Acyl-Coenzyme A oxidase 1, palmitoyl 
ACSL6 23305 Acyl-CoA synthetase long-chain family member 
6 
ADH6 130 Alcohol dehydrogenase 6 (class V) 
ADSSL1 122622 Adenylosuccinate synthase like 1 
AGTRAP 57085 Angiotensin II receptor-associated protein 
AHSA2 130872 Activator of heat shock 90kDa protein ATPase 
homolog 2 
AKAP1 8165 A kinase (PRKA) anchor protein 1  
ANG 283 Angiogenin, ribonuclease, RNase A family, 5 
ANKRD38 163782 Ankyrin repeat domain 38 
APOH 350 Apolipoprotein H (beta-2-glycoprotein I) 
APOL1  APOL1 
AQP3 360 Aquaporin 3 (Gill blood group) 
ART4 420 ADP-ribosyltransferase 4 (Dombrock blood 
group) 
ATN1 1822 Atrophin 1 
AURKAIP1 54998 Aurora kinase A interacting protein 1  
BAI3   Brain-specific angiogenesis inhibitor 3 
BCL2A1 597 BCL2-related protein A1 
CA3 761 Carbonic anhydrase III, muscle specific 
CAMK2N1 55450 Calcium/calmodulin-dependent protein kinase II 
inhibitor 1 
CCL2 6347 Chemokine (C-C motif) ligand 2 
CCL4L2 388372 Chemokine (C-C motif) ligand 4-like 2 
CD55 1604 CD55 molecule, decay accelerating factor for 
complement  
CDC25B 994 Cell division cycle 25 homolog B 
CDH1 999 Cadherin 1, type 1, E-cadherin (epithelial) 
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CDKN1B 1027 cyclin-dependent kinase inhibitor 1B (p27) 
CEP68 23177 Centrosomal protein 68kDa 
CNTN1 1272 Contactin 1 
COL5A1 1289 Collagen, type V, alpha 1  
COMMD6 170622 COMM domain containing 6 
COMP 1311 Cartilage oligomeric matrix protein  
CP 1356 Ceruloplasmin (ferroxidase) 
CXCL1 2919 Chemokine (C-X-C motif) ligand 1  
CYB5A 1528 Cytochrome b5 type A (microsomal) 
CYP27A1 1593 Cytochrome P450, family 27, subfamily A, 
polypeptide 1 
DHRS3 9249 Dehydrogenase/reductase (SDR family) member 
3 
DIO2 1734 Deiodinase, iodothyronine, type II 
DLGAP4 22839 Discs, large (Drosophila) homolog-associated 
protein 4 
DNAJB9 4189 DnaJ (Hsp40) homolog, subfamily B, member 9 
DNAJC4 3338 DnaJ (Hsp40) homolog, subfamily C, member 4 
DR1 1810 Down-regulator of transcription 1, TBP-binding 
(negative cofactor 2) 
ERLEC1 27248 Endoplasmic reticulum lectin 1  
ETFB 2109 Electron-transfer-flavoprotein, beta polypeptide 
FAF1 11124 Fas (TNFRSF6) associated factor 1 
FAM80B 57494 Family with sequence similarity 80, member B 
FETUB 26998 Fetuin B 
FGFRL1 53834 Fibroblast growth factor receptor-like 1 
FKBP2 2286 FK506 binding protein 2, 13kDa 
FN1 2335 Fibronectin 1 
FRAS1  FRAS1 
FUCA1  FUCA1 
FVT1 2531 Follicular lymphoma variant translocation 1 
GABARAPL1 23710 GABA(A) receptor-associated protein like 1 
GABPA 2551 GA binding protein transcription factor, alpha 
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subunit 60kDa 
GFM1 85476 G elongation factor, mitochondrial 1 
GIYD2 79008 GIY-YIG domain containing 2 
GK2 2712 Glycerol kinase 2  
GLIPR1 11010 GLI pathogenesis-related 1 (glioma) 
GLRX 2745 Glutaredoxin (thioltransferase) 
GNAO1 2775 Guanine nucleotide binding protein (G protein),  
alpha activating activity polypeptide O 
GOLGA2 2801 Golgi autoantigen, golgin subfamily a, 2 
GPX2 2877 Glutathione peroxidase 2 (gastrointestinal) 
GTF2B 2959 General transcription factor IIB  
HIST1H1C 3006 Histone cluster 1, H1c 
HIST2H2BE 8349 Histone cluster 2, H2be 
HMGN3 9324 High mobility group nucleosomal binding 
domain 3 
HSD17B8 7923 Hydroxysteroid (17-beta) dehydrogenase 8 
HYAL1 3373 Hyaluronoglucosaminidase 1 
IFITM2 3459 Interferon gamma receptor 1 
IFNGR1 10581 Interferon induced transmembrane protein 2 
(1-8D) 
IGF1R 3480 Insulin-like growth factor 1 receptor 
IGFBP1 3484 Insulin-like growth factor binding protein 1 
IGFBP3 3486 Insulin-like growth factor binding protein 3 
IGFBP6 3489 Insulin-like growth factor binding protein 6 
IL32 9235 Interleukin 32 
INSL4 3641 Insulin-like 4 (placenta) 
IPCEF1 26034 interaction protein for cytohesin exchange factors 
1  
IQGAP2 10788 IQ motif containing GTPase activating protein 2 
IRF2 3660 Interferon regulatory factor 2 
IRF2BP2 359948 Interferon regulatory factor 2 binding protein 2 
IRF8 3394 Interferon regulatory factor 8 
IRF9 10379 Interferon regulatory factor 9 
102 
 
ISG15 9636 ISG15 ubiquitin-like modifier 
ISG20 3669 Interferon stimulated exonuclease gene 20kDa 
JMJD3 23135 Jumonji domain containing 3 
KANK4 163782 KN motif and ankyrin repeat domains 4  
KLHDC8B 200942 kelch domain containing 8B  
LGALS3BP 3959 Lectin, galactoside-binding, soluble, 3 binding 
protein 
LRRC56 115399 Leucine rich repeat containing 56 
LTB4DH 22949 Leukotriene B4 12-hydroxydehydrogenase 
MALAT1 378938 Metastasis associated lung adenocarcinoma 
transcript 1  
MAPK1 5594 Mitogen-activated protein kinase 1 
MAPK4 5596 Mitogen-activated protein kinase 4 
METTL7A 25840 Methyltransferase like 7A 
METTL10 399818 Methyltransferase like 10  
MFAP5 8076 Microfibrillar associated protein 5  
MMP15 4324 Matrix metallopeptidase 15 
MOBKL2C 148932 MOB1, Mps One Binder kinase activator-like 2C 
(yeast) 
MPP7 143098 Membrane protein, palmitoylated 7 (MAGUK 
p55 subfamily member 7) 
MSX2  MSH homeobox 2  
MX1 4599 Myxovirus (influenza virus) resistance 1,  
interferon-inducible protein p78 (mouse) 
MYL6B 140465 Myosin, light chain 6B, alkali, smooth muscle 
and non-muscle 
NCSTN 23385 Nicastrin 
NDUFB1 4707 NADH dehydrogenase (ubiquinone) 1 beta 
subcomplex, 1, 7kDa 
NICN1 84276 Nicolin 1 
NRARP 441478 NOTCH-regulated ankyrin repeat protein  
NRP2 8828 Neuropilin 2 
NXF1 10482 Nuclear RNA export factor 1  
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OAZ2 4947 Ornithine decarboxylase antizyme 2 
PAPPA 5069 Pregnancy-associated plasma protein A, 
pappalysin 1 
PDGFRL 5157 Platelet-derived growth factor receptor-like 
PDK4 5166 Pyruvate dehydrogenase kinase, isozyme 4 
PFDN5 5204 Prefoldin subunit 5 
PLSCR1 5359 Phospholipid scramblase 1 
PLXNA2 5362 Plexin A2 
PNKD 25953 Paroxysmal nonkinesigenic dyskinesia 
PNPLA4 8228 Patatin-like phospholipase domain containing 4 
POLD4 57804 Polymerase (DNA-directed), delta 4 
POLR1D 51082 Polymerase (RNA) I polypeptide D, 16kDa 
PON3 5446 Paraoxonase 3 
PPWD1 23398 Peptidylprolyl isomerase domain and WD repeat 
containing 1  
PRRG4 79056 Proline rich Gla (G-carboxyglutamic acid) 4  
PSME1 5720 Proteasome (prosome, macropain) activator 
subunit 1 (PA28 alpha) 
PSME2 5721 Proteasome (prosome, macropain) activator 
subunit 2 (PA28 beta) 
PTGS2 5743 Prostaglandin-endoperoxide synthase 2  
RAB31 11031 RAB31, member RAS oncogene family 
RAP1GDS1 5910 RAP1, GTP-GDP dissociation stimulator 1 
RARB 5915 Retinoic acid receptor, beta  
RARG 5916 Retinoic acid receptor, gamma  
RARRES1 5918 Retinoic acid receptor responder (tazarotene 
induced) 1 
RBPJ 3516 Recombination signal binding protein for 
immunoglobulin kappa J region 
S100P 6286 S-100P PROTEIN 
SAT1 6303 Spermidine/spermine N1-acetyltransferase 1 
SCNN1A 6337 Sodium channel, nonvoltage-gated 1 alpha 
SERINC2 347735 Serine incorporator 2 
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SERPINB1 1992 Serpin peptidase inhibitor, clade B (ovalbumin), 
member 1 
SHROOM1 134549 Shroom family member 1 
SIP1 8487 Survival of motor neuron protein interacting 
protein 1 
SLC16A3 9123 Solute carrier family 16, member 3 
(monocarboxylic acid transporter 4) 
SLC23A2 9962 Solute carrier family 23 (nucleobase 
transporters), member 2 
SLC25A29 123096 Solute carrier family 25, member 29 
SLC29A4 222962 Solute carrier family 29 (nucleoside transporters), 
member 4 
SLC36A4 120103 Solute carrier family 36 (proton/amino acid 
symporter), member 4 
SLC7A2 6542 solute carrier family 7 (cationic amino acid 
transporter), member 2 
SLC7A7 9056 Solute carrier family 7 (cationic amino acid 
transporter), member 7 
SMPDL3A 10924 Sphingomyelin phosphodiesterase, acid-like 3A  
SNHG7 84973 Small nucleolar RNA host gene (non-protein 
coding) 7 
SOD2 6648 Superoxide dismutase 2, mitochondrial 
SP100 6672 SP100 nuclear antigen 
ST3GAL4 6484 ST3 beta-galactoside alpha-2,3-sialyltransferase 4 
STX17 55014 syntaxin 17  
SYNPO2L 79933 Synaptopodin 2-like  
TBC1D23 55773 TBC1 domain family, member 23 
TBR1 10716 T-box, brain 1  
TC2N 123036 Tandem C2 domains, nuclear 
TCEA2 6919 Transcription elongation factor A (SII), 2 
TCN2 6948 Transcobalamin II; macrocytic anemia 
TGOLN2 10618 Trans-golgi network protein 2  
TIGD2 166815 Tigger transposable element derived 2 
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TIPIN 54962 TIMELESS interacting protein  
TMEM11 8834 Transmembrane protein 11 
TMEM37 140738 Transmembrane protein 37 
TNRC18 84629 TNRC18 
TOB1 10140 Transducer of ERBB2, 1 
TOMM70A 9868 Translocase of outer mitochondrial membrane 70 
homolog A (S. cerevisiae) 
TP53I11 9537 Tumor protein p53 inducible protein 11 
TSPAN7 7102 Tetraspanin 7 
U2AF2 11338 U2 small nuclear RNA auxiliary factor 2 
UBD 10537 Ubiquitin D 
UQCR 10975 Ubiquinol-cytochrome c reductase, 6.4kDa 
subunit 
USP12 219333 Ubiquitin specific peptidase 12  
USP34 9736 Ubiquitin specific peptidase 34 
UTRN 7402 Utrophin  
WHSC2 7469 Wolf-Hirschhorn syndrome candidate 2  
ZNF219 51222 Zinc finger protein 219 
ZNF525 170958 Zinc finger protein 525 
ZNF599 148103 Zinc finger protein 599 
ZNF616 90317 Zinc finger protein 616 
ZNRF1 84937 Zinc and ring finger 1 
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9.7. Abbreviations 
 
ATM ataxia telaniectasia mutated 
bp base pair 
CDK cyclin-dependent kinase  
cDNA complementary DNA 
Ct threshold cycle  
CT comparative threshold  
DMSO dimethyl sulfoxide 
DNA deoxyribonucleic acid 
DNase deoxyribonuclease 
DSB double stands break  
dNTPs deoxynucleotide triphosphates 
EDTA ethylene diamine tetraacetic acid 
FBS fetal bovine serum 
FDR false discovery rate 
GAPDH Glyseraldehyde-3-phosphate dehydrogenase 
GLRX Glutaredoxin 
GO The Gene Ontology Consortium  
GSI Gesellschaft für Schwerionenforschung  
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HI heavy ion  
IMT Molecular Biology and Tumor Research,  
 University Marburg 
IPA Ingenuity Pathway Analysis 
LET linear energy transfer  
mRNA messenger RNA 
MRP multidrug resistance-associated protein  
NSCLC non-small cell lung cancer 
nt nucleotide 
OD optical density 
OSCC oral squamous cell carcinoma  
PBS phosphate-buffered saline 
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PCR polymerase chain reaction 
qRT-PCR quantitative RT-PCR 
RBE relative biological effectiveness 
rmp round per minute 
RNA ribonucleic acid 
RNAase ribonuclease 
RT room temperature 
RT-PCR real time PCR 
SDS sodium lauryl sulfate 
SSC saline-sodium citrate buffer 
TAE Tris-Acetate- EDTA buffer 
Tris Tris (hydroxymethyl) aminomethane 
UV ultraviolet radiation 
MW molecular weight 
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